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    Normal glandular epithelial tissues are composed of a simple layer of epithelial cells 
that adopt apical–basal polarity, where the basal side contacts the basement membrane 
(BM) and the apical side is opposite the fluid-filled lumen. In some glandular 
epithelium there is a basal or myoepithelial cell layer that separates the luminal 
epithelium from the interstitial extracellular matrix (ECM) (Barsky and Karlin, 2005). 
Epithelial tissue homeostasis depends on the maintenance of tissue organization and a 
dynamic dialogue with a surrounding stroma composed primarily of non-activated 
fibroblasts and adipocytes, and a steady-state population of transiting, non-stimulated 
leukocytes (Ronnov-Jessen, 1996). Thus, non-activated tissue fibroblasts secrete and 
organize type I and III collagens, elastin, fibronectin, tenascin and a repertoire of 
proteoglycans (hyaluronic acid and decorin), which all maintain the structural and 
functional integrity of the interstitial ECM. Most glandular epithelial tissues including 
breast, saliva gland, lung, pancreas and prostate are in a state of tensional homeostasis 
so that their normal state is highly mechanically compliant (Paszek and Weaver, 2004). 
 
 
Tumor microenvironment 
Cancer is the loss of tissue organization and aberrant behaviour of the cellular 
components. Tumor microenvironment is enriched of multiple non-malignant, albeit 
altered, cell types – fibroblasts, endothelial cells and leukocytes – all of which interact, 
either physically or via the secretion of paracrine signaling molecules with tumor 
epithelial cells (Fig 1) (reviewed in Xu, 2009). There is an intricate mutually sustaining 
synergy between the tumor epithelial cells and their surrounding stroma. The 
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relationship of these cells with tumorigenesis is complex; they can possess tumour 
suppressing properties but are frequently polarised into invasion and metastasis 
promoting roles as tumours progress. The structural support for these various cell types 
is provided by the ECM. These components do not function in isolation but 
communicate through a variety of mechanisms.  
Compelling evidence has emerged in recent years for activated stromal cells playing an 
important role in tumor cell invasion into surrounding normal tissues, proliferation and 
survival, and metastasis to local and distant sites (Paraic, 2010). Activated stromal cells 
act either releasing chemotactic factors, modifying interstitial tissue around tumor cells 
or promoting actively tumor cell migration. Many studies have demonstrated a  
prominent role for soluble factors in communication between different cell types in the 
tumour environment. The production of chemokines, such as CCL2, CCL5, CCL9, 
CXCL12 (SDF-1a), and cytokines, such as TNFa, CSF-1, IL-1 and IL-6, by cancer cells 
recruits a range of leukocytes including macrophages, myeloid derived suppressor cells 
(MDSCs), T-cells and neutrophils (Mantovani, 2008). On the other hand, stromal cells 
release autocrine and paracrine signals which mediate pro-migratory, anti-apoptotic and 
inflammatory stimuli in cancer cells. For example, resident fibroblasts receive 
activation signals through growth factors (TGFβ, Il-1) developing into cancer associated 
fibroblasts (CAFs). They are able to modify the properties of the ECM through altered 
expression of structural components such as collagen, fibronectin and tenascin-C 
isoforms and ‘matricellular’ proteins (Egeblad, 2010). ECM deposition and remodelling 
by CAFs increased cancer cell migration, as observed in murine squamous cancer cells 
(Caggioli, 2007).  
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Tumor tissue remodelling is required for a cancer cell to degrade physical barriers 
during local expansion and intravasation at nearby blood vessels, extravasation and 
invasion at a distant location, through multiple protease systems which are up-regulated 
in tumor cells. These systems include matrix-metalloproteinases (MMPs), ADAMs, 
cathepsins, the serine protease urokinase plasminogen activator (uPA) (Mason and 
Joyce, 2011). Upregulated proteases contribute to tumor invasion and progression 
through at least three mechanisms (Wolf and Friedl, 2011). First, they execute 
proteolysis of structural ECM proteins, including fibrillar and nonfibrillar collagens, 
fibronectin, and laminin (Wolf, 2007). Second, they process other proteases or surface 
receptors, including adhesion and growth factor receptors (Overall and Blobel, 2007). 
Finally, they regulate the repertoire of available extracellular growth factors 
(Kessenbrock, 2010). In fact, MMPs and ADAMs can release ECM-bound factory 
which then form diffusing gradients toward neighbour cells (Shiao and Coussens, 
2010). 
The molecular and physical characteristics of the ECM strongly modulate tumor cell 
activities and invading cancer cells often simultaneously integrate signals from soluble 
factors and ECM molecules (laminins, collagens, fibronectin). The density of collagen 
fibers is often increased (Franz, 2010), promoting integrin activation and consequently 
cancer cell migration (Even-Ram, 2005). Most ECM proteins undergo enzymatic 
postprocessing; for example collagens, when glycosilated, increase their stiffness and 
resistance to proteolytic degradation (Levental, 2009). This increased stiffness enhances 
the clustering of integrins and focal adhesion formation augmenting both cell 
contractility and mesenchymal functions (Levental, 2009). 
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The physical tissue properties determine consequences for cell growth and 
differentiation (Discher 2005). As a central downstream signaling pathway that connect 
mechanotransduction to gene expression, cell proliferation in response to substrate 
stiffness is regulated by Yap1, a transcription factor downstream of the hippo pathway 
(Dupont, 2011). Yap1 supports also epithelial stem cell growth and proliferation 
(Schlegelmilch 2011). 
The inflammation is often associated with tumors and may contribute to the so-called 
reactive stroma, a stroma with an increased number of fibroblasts, enhanced capillary 
density and type I collagen. The presence of leukocytes in tumors in the past was 
generally thought to be a consequence of a failed attempt at cancer cell destruction. 
However tumors are not only effective in escaping from immune-mediated rejection, 
but they also modify certain inflammatory cell types to render them tumor promoting 
rather than tumor suppressive. Depending on the tissue context, CD4+ T cells, 
macrophages and NKT cells have either tumor-suppressive or tumor-promoting 
properties (De Visser 2006).  
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Figure 1. Communication networks in cancer invasion. Components of the network are shown in grey 
boxes with italics. Mechanisms of communication are indicated with coloured arrows and specific 
mediators are in white text boxes. Cancer cells sit at the centre of the network modulating the recruitment 
and activation of cellular and non-cellular environmental components. In turn, these components may 
regulate the invasive behaviour of the cancer cell by diverse mechanisms (depicted in different colours). 
Yellow, soluble factors; violet, proteases; grey, ECM remodelling proteins; orange, ECM-released GFs; 
black, mechanical signalling; dark red, cell–cell contacts; and red, oxygen tension. TNC, tenascin-C; FN, 
Fibronectin; OPN, Osteopontin. Adapted from “ Calvo F et al (2011) Cell communication networks in 
cancer invasion. Current Opinion Cell Biology”. 
 
 
Epithelial-to-Mesenchymal Transition  
About 90% of human malignancies are carcinomas, tumors of epithelial origin. The 
early steps in carcinoma metastasis often bear a striking resemblance to developmental 
programs involving Epithelial-to-Mesenchymal Transition (EMT), a process that 
converts organized epithelial cells into isolated, migratory cells with a mesenchymal 
morphology. EMT plays a critical role in early developmental processes, such as 
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gastrulation, leading to formation of mesoderm and during neural crest formation 
determining the release of mesenchymal cells that migrate through the body, generating 
the vertebrate head and awide variety of tissue types, including glial and neuronal cells, 
adrenal glandular tissues, melanocytes, and skeletal and connective tissues (reviewed in 
Nisticò, 2012). Several evidences implicate EMT-like mechanisms in tumor cell 
invasion and in experimental systems and, recently, in human cancer. Normal epithelia 
are comprised of cells with aligned apical-basal polarity that are interconnected laterally 
by several types of junctions, which play important roles in establishing and regulating 
cell-cell adhesion. During EMT, apico-basolateral polarity is lost, cell-cell junctions 
dissolve and the actin cytoskeleton is remodeled to endow cells with mesenchymal 
characteristics, including an elongated, migratory and invasive phenotype. Importantly, 
as a consequence of EMT cells may escape tumors, invade the surrounding tissue and 
migrate towards blood or lymphatic vessels guided by the cells and extracellular matrix 
present in their microenvironment (Fig 2). 
EMT can be prompted by various intrinsic signals (e.g. gene mutations) as well 
extrinsic signals (e.g. growth factor signaling). Among the growth factors known to 
induce EMT are TGFβ, HGF, members of the EGF family, IGF, and FGF (Yilmaz, 
2009). Notch signaling has been implicated in EMT in human breast cancer cells by 
activating the transcription factor Slug, a potent repressor of E-cadherin gene expression 
(Leong, 2007). Changes in the composition of the ECM are also able to induce EMT, as 
shown for collagen I (Shintani, 2006). These signals are able to mediate the 
transcriptional repression of E-cadherin by a list of transcription factors, among them 
intensely studied factors like Snail1 (Snail), Snail2 (Slug), ZEB1 (δEF1), ZEB2 (Sip1) 
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and Twist (Peinado, 2007). Engagement of these transcriptional repressors at the E-
cadherin gene promoter eventually leads to epigenetic silencing of the gene by histone 
modifications (acetylation, methylation, phosphorylation, ubiquitinylation, 
sumoylation) and subsequently by DNA hypermethylation (Kouzarides, 2007). EMT is 
often driven by repressing expression of E-cadherin but recent reports demonstrate that 
EMT occurs also in presence of E-cadherin. In Drosophila, E-cadherin mRNA 
expression is maintained throughout Serpent-induced EMT, which does not involve 
Snail or Zeb orthologs (Campbell, 2011). The authors also find this  Serpent-regulated 
EMT in a mammalian cell line. Specifically, GATA-4 and GATA-6, two mammalian 
orthologs of Serpent, induce EMT in MDCK cells. Furthermore, GATA-6 induces actin 
cytoskeletal remodeling, lamellipodia formation, and subsequent cell motility and 
invasion.  
Most studies of EMT in the context of cancer biology have been conducted in vitro, and 
thus the relevance of EMT to carcinogenesis continues to be debated (Ledford, 2011). If 
EMT does play a crucial role in cancer cell spread in vivo, then detection methods that 
rely on cellular expression of epithelial markers alone are likely to provide an 
incomplete picture of metastasis.  
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Figure 2. The epithelial-to-mesenchymal transition (EMT) is associated with a loss of adhesion through 
downregulation of E-cadherin (E-cad) and a change in morphology. Invasion by tumour cells of the 
surrounding tissue and subsequent motion is dictated by the physicochemical properties of the 
extracellular matrix (ECM). By squeezing between blood vessel endothelial cells, tumour cells can enter 
the vascular system. All of these steps involve physicochemical processes, such as adhesion and 
deformation, that are dependent on the local environment. Adapted from “ Wirtz et al (2011) The physics 
of cancer: the role of physical interactions and mechanical forces in metastasis. Nat Rev Cancer ” 
 
Actin cytoskeleton dynamics role in Cell adhesion and Cell migration 
The actin cytoskeleton is a highly dynamic structure, which is constantly remodeled in a 
living cell. This dynamics are based on a well-balanced and highly controlled 
equilibrium of local assembly and disassembly of actin filaments. Obviously, such 
regulation is a prerequisite for processes like endocytosis, cell morphology, cell 
adhesion, cell motility, and cancer cell invasion (Yilmaz, 2009).  Cell adhesion and cell 
migration coordination required interaction of many different molecules and signaling 
pathways, but the actin cytoskeleton and regulators of actin dynamics held a 
determinant role in all processes. Each actin regulators, in turn, is controlled by several 
signaling molecules, usually including Rho GTPases, membrane phospholipids and 
protein phosphorylation. Understanding adhesion turnover in migrating cells and the 
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mechanisms underlying this process is now a critical area of emerging interest. 
 
 
Cell adhesion in normal epithelium 
A normal epithelium is able to either maintain tissue architecture or facilitate cell 
movement through dynamic changes in cell adhesion in order to resolve and establish 
new cell contacts during developmental cell movements, tissue renewal and wound 
repair. Intercellular adhesions are essential for compartmentalization and integrity of 
tissues in an organism, cell-cell communication and morphogenesis. Critical in 
mediating cell-cell interaction, adherens junctions (AJs) are formed primarily by 
cadherin family adhesion receptors and are strengthened by the actin cytoskeleton, 
which interacts with cadherins through additional proteins. The cytoplasmic tail of 
classic cadherins binds to -catenin and once at the plasma membrane, the cadherin--
catenin complexes recruits -catenin. The latter is essential for AJs formation and 
function and operates at the interface of the cadherin-catenin complex and the actin 
cytoskeleton (reviewed in Harris & Tepass,  2010). 
AJs are especially important for epithelial and endothelial cells that line the tissue 
surfaces and therefore should form cohesive sheets to resist mechanical challenges and 
maintain tissue integrity. In epithelial cells, AJs exist in two forms, as stable linear 
zonular adherens forming circumferential rings around the apical cell surface in 
polarized cells, and as dynamic punctate discontinuous junctions characteristic for 
tissues undergoing remodeling or neoplastic transformation (Ayollo, 2009; Taguchi, 
2011). E-cadherin is the prototype family member of classical cadherins, single-span 
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transmembrane glycoproteins that interact in a calcium-dependent, homophilic manner 
with E-cadherins on neighboring cells.  
Observations of cell-cell contact initiation in various epithelial cells suggest that the 
initial contact between cells is made through activity of actin-rich protrusions, 
lamellipodia and filopodia (Fig 2) (Mattila and Lappalainen, 2008). Within the 
lamellipodium, the actin filaments form a branched network with barbed ends facing the 
leading edge (Svitkina, 1997; Svitkina and Borisy, 1999). Filopodia, often originating 
from lamellipodia (Svitkina, 2003), are thin bundles of long actin filaments also 
oriented with their barbed ends toward the filopodium tip. Studies of cell-cell junction 
formation in primary keratinocytes suggested that the initial contact commences with 
interdigitating filopodia that establish a series of point contacts, which subsequently 
zipper into a continuous cell-cell junction (Raich, 1999; Vasioukhin, 2000; Vasioukhin 
and Fuchs, 2001). 
As AJs assemble, cadherin-catenin clusters actively transform the actin cytoskeleton, 
initially co-opting cell protusions to expand cell contacts and ultimately reconfiguring 
actin into a circumferential belt to support cell-cell adhesion. Inhibition of the actin 
remodelling proteins, such as Arp 2/3, Ena/VASP or formins, distrupts AJ organization 
(Verma, 2004; Vasioukhin, 2000). Since these proteins are active at cell protusions 
before cell-cell contact is made and are also involved to cell migration pathways, 
cadherin-catenin clusters must co-opt these factors from cell migration signals for use in 
AJs assembly.  
The small GTPases Rac1, RhoA and Cdc42 are downstream to cadherin-catenin clusters 
and a fine balance between their activity is fundamental for AJs assembly and the 
  
 
 
 
 17 
maintenance of an epithelial structure (Braga, 2000). During de-novo contacts between 
stationary epithelial cells, Rac1 and RhoA have different roles in initiating adhesive 
contacts (Rac1) and expanding and completing the contact (RhoA) (Yamada, 2011). 
GTPases coordination can be mediated by upstream signals, such as Abelson Kinase 
activation (Zandy, 2007) or by the recruitment of many GTPase activating proteins 
(GAP) or guanine nucletodice exchange factors (GEF), that are key regulators of small 
GTPases, with GEFs promoting activation to the GTP bound state and GAPs promoting 
inactivation by stimulating GTP hydrolysis (Bos, 2007). 
 
 
Cell migration in normal epithelium 
Cell migration underlies tissue formation, maintenance and regeneration as well as 
pathological conditions such as cancer invasion. For most cells, including epithelial, 
stromal or neuronal cells, migration phases are confined to morphogenesis and cease 
with terminal differentiation toward intact tissue to become reactived only for tissue 
regeneration or neoplastic processes. For other cell types, such as leukocytes, migration 
maintained throughout their life span.  
Cell migration is a coordinated event involving polarization, protrusion, adhesion to the 
ECM, tissue remodelling through proteolysis of ECM,  myosin II-driven contraction of 
the cell body, and adhesion disassembly at the cell rear. The first step of cell migration 
is a morphological polarization that cell must acquire in order to generate intracellular 
forces that produce a net body translocation. A master regulator of cell polarity in 
eukariotic organisms ranging from yeast to humans, is Cdc42 (Heasman and Ridley, 
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2008). Cdc42 together with Rac and RhoG, are the main activators of the 
WASP/WAVE-Arp2/3 complex pathway, leading to formation of a branched actin 
network and extension of lamellipodia. In order to move, cells must extend their plasma 
membrane foward at the front, or “leading edge”, of the cell, through specialized actin 
structures such as lamellipodia, filopodia, blebs and invadopodia (reviewed in Ridley 
2011). A protrusion must form and then stabilize by attaching to the surrounding 
matrix. Different kind of cell-matrix adhesions are described, based primarily on 
morphology or method of formation, including focal adhesions, fibrillar adhesions, 
focal complexes and podosomes. For example, fibrillar adhesions are central structures 
that contain α5β1 integrin, tensin and actopaxin (Zamir, 2000), whereas focal 
complexes are small adhesions induced by Rac activation at the periphery of the cell 
(Rottner, 1999). It is the small adhesions at the cell front, undetectable in some cell 
types, that drive rapid cell migration (Svitkina, 1997). Under tension, these small 
adhesions can mature into larger, more organized adhesions, such as focal adhesions 
(Balaban, 2001). Focal adhesions, which have been intensively studied, are relatively 
stable structures and tend to inhibit cell migration. They seem to be involved in the 
generation of contractile forces that function in processes unrelated to migration, such 
as the formation and remodeling of extracellular matrices (Geiger, 2001). 
Integrins are the major family of migration-promoting receptors and may act as “feet” 
of a migrating cell supporting adhesion on ECM. Integrins link ECM to the actin 
cytoskeleton and may activate signaling cascades, so Integrins are molecules that allow 
an “inside-out signaling”. Integrins are heterodimeric receptors with large ligand-
binding extracellular domains and short cytoplasmic domains. The binding of ligands 
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confers conformational changes in the receptor that leads to receptor clustering, that 
initiate intracellular signaling such as protein phosphorylation, activation of small 
GTPases, change in phospholipids biosynthesis. This is linked to formation and 
strenghting of adhesion sites and organization and dynamics of the actin cytoskeleton 
(Geiger, 2001). The mechanism by which adhesions assemble in migrating cells is still 
not well understood. It may starts with little focal contacts, dependent on Cdc42 and 
Rac that stabilize the lamellipodium by mediating attachments to ECM.  
A migrating cell must be able to protrude and then detach from the older adhesions in 
order to move. By connecting the ECM to the intracellular cytoskeleton, integrins serve 
as both traction sites over which the cell moves and as mechanosensors, transmitting 
information about the physical state of  the ECM into the cell and altering cytoskeletal 
dynamics (Galbraith, 2002). The force transmitted to sites of adhesion derives from the 
interaction of myosin II with actin filaments that attach to these sites. Myosin II activity 
is regulated by myosin light-chain (MLC) phosphorylation. MLC phosphorylation 
activates myosin, resulting in increased contractility and transmission of tension to sites 
of adhesion. 
At the rear of migrating cells, adhesion must also disassemble. The cell rear is a region 
where Integrin-cytoskeletal linkages tend not to form and the membrane is not well 
supported by the cytoskeleton network. The Rho/ROCK/MLC/Myosin II pathway is 
implicated in the high tension exerted on the rear adhesions and contributes to the 
detachments (Riento and Ridley 2003). 
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Cell adhesion and Cell migration in tumor cells 
Cancer cells recaputilate the types and mechanisms of migration used by normal cells. 
They activate the same machineries for changing shape, generating force and 
remodelling ECM (Friedl, 2004), as normal cells, but neoplastic cells lack phisiological 
“stop signals” (Cox, 2001). Since cell migration, cell adhesion and cell shape depend on 
the actin cytoskeleton and actomyosin contractility there has been much interest how 
they are controlled by cell signalling mechanisms.  
To detach from the primary tumor and to invade into the surrounding tissue, tumor cells 
have to break down cell-cell contacts, remodel cell-matrix adhesion sites, and follow a 
chemoattractive path through the extracellular matrix, mined by secreted proteinases 
(reviewed in Ridley, 2011). These processes are commonly observed in various non-
pathological conditions, such as in developmental processes like gastrulation or neural 
crest cell migration, where differentiated, epithelial cells dedifferentiate, move to a 
distant site, and then re-differentiate to form a new structure.  
Each of these steps requires a distinct molecular program in which the modulation of 
the adhesive and migratory and, thus, the cytoskeletal properties of the disseminating 
tumor cells play essential roles.  
 
 
Physical and Molecular Determinants of Invasion 
    Abnormal cell migration and tissue invasion occurs frequently in cancer and is an 
essential component of metastasis, the major clinical problem in cancer. Depending on 
the cell type and tissue environment, cells can migrate in two major ways: individually, 
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when cell-cell junctions are absent, or collectively as multicellular groups, when cell-
cell adhesions are retained (Friedl and Wolf, 2010). Invasive single-cell migration in 
turn divides into ameboid/rounded and mesenchymal migration, depending on cell 
morphology, actomyosin-mediated contractility and proteolytic activity. The molecular 
mechanisms underlying each migration mode depend on a set of connected mechanical 
and signaling pathways, which vary in their coordination and strenght depending on the 
particular migration mode (Sanz-Moreno and Marshall, 2010).  
Actin cytoskeleton is involved in the generation of localised structures such as 
protrusions and adhesions between cells and to the matrix (Fig 3). The latter linked to 
the actin cytoskeleton through integrins. In particular, after associating with matrix-
derived ligands, the cytoplasmic tails of integrins connect to cytoskeletal adaptor 
proteins and activate protein kinases, including focal adhesion kinase (FAK) and Src 
(Geiger, 2009). They might regulate migration by modulating the phosphorylation and 
dephosphorylation of key adaptor molecules in adhesions. For example, the FAK–Src 
complex mediates the phosphorylation of two well-known scaffolding molecules, 
paxillin and p130 Crk-associated substrate (CAS) that  can recruit other molecules to 
adhesions and regulate the organization of the actin cytoskeleton (Bellis 1995, Cary 
1998). 
It has fully demonstrated that the integrins play important role in tumor progression. 
The shifting profile of integrin receptor expression may promote tumor cell survival and 
migration in multiple tissues with different matrix compositions (Guo and Giancotti, 
2004; Wilhelmsen, 2006). Increased expression of the integrin b1 subunit correlates 
with decreased breast cancer survival, whereas other integrin receptors such as avb3 and 
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a6b4 are induced in highly metastatic melanoma cells and pancreatic adenocarcinoma 
progression, respectively (Desgrosellier, 2010). Changes in the expression of the 
integrin-associated proteins FAK, paxillin, a-actinin, and vinculin are also observed 
during tumor progression. Tumor cells appear to take advantage of the ability of FAK to 
regulate pathways important for cell proliferation, cell migration, gene expression, and 
survival (Mitra, 2005; Slack-Davis, 2007). For instance, FAK expression and activity 
are enhanced in metastatic tumors of the oral cavity, colon, rectum, thyroid, prostate, 
and cervix. In ovarian cancer, increased FAK expression correlates with decreased 
patient survival (Brunton, 2008). In breast carcinoma, FAK activity is important for 
VEGF expression and tumor angiogenesis (McLean, 2005). Similar to FAK, increased 
expression of paxillin is observed in breast carcinoma, and a-actinin expression levels 
are increased in melanomas and in tumor cell lines with faster migration rates 
(Vadlamudi, 1999). 
Downstream integrin effectors further include the small GTPases Rho, Rac, and Cdc42, 
have all been linked to cell movement (Ridley, 2003) and are deregulated in some 
tumors and correlates with progression of disease (Sahai and Marshall, 2002). Rac1 
drives motility by promoting lamellipodia formation (Ridley, 1992), whereas RhoA 
signals to the kinases ROCKI and II, promoting the formation of actin stress fibers and 
generation of the actomyosin contractile force required for cell movement (Kimura, 
1996). Melanoma cell movement analysis demonstrated that rounded/amoeboid forms 
of movement are driven by high actomyosin contractility through Rho and Cdc42 
signalling while Rac signalling is required for actin assembly in elongated-protrusive 
movement (Sanz-Moreno, 2008).   
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Receptors that transmit cell-cell adhesion forces toward the actin cytoskeleton support 
single-cell and collective movement along the surfaces of other tissue-resident cells. 
Different sets of cadherins are expressed depending on the type of tumor and they show 
duality in delivering both migration-inhibiting and migration-promoting signaling in a 
context-dependent manner. In fact, in polarized resting epithelium, E-cadherin 
suppresses migration signaling by inhibiting Rac1 activation (Kitt and Nelson, 2011), 
whereas in activated and neoplastic cells E-cadherin and other cadherins coordinate 
collective movement (Friedl and Glimour, 2009).  
Another cell adhesion molecules involved to cancer invasion belong to the 
Immunoglobulin superfamily of cell adhesion molecules (CAM). Among them, 
L1CAM is up-regulated in the leading edge of collectively invading epithelial tumors 
(Bergmann, 2010). Similar to leukocytes, tumor cells develop heterophilic cell-cell 
interactions with endothelial cells or platelets and these interactions occur between 
endothelial cells expressing CAMs and neoplastic cells expressing specific integrins, 
allowing intravasation and extravasation of tumor cells (Zecchini, 2011). 
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Figure 3. Molecular Determinants of Cell MigrationSimplified view of molecules mediating adhesion and 
migration signaling.(A) Cell surface receptors and adaptors that mediate the dynamic interface between 
the actin cytoskeleton and promigratory signaling and the extracellular matrix (ECM).(B) Cell surface 
proteins that mediate and regulate interactions between cells. Similar adhesion mechanisms may mediate 
homotypic cell-cell cohesion during collective invasion and transient and more dynamic heterophilic 
interaction to resident tissue cells encountered during tissue invasion.(C) Protease systems upregulated 
in cancer progression, invasion, and metastasis.(D) Receptors for chemokines, cytokines, and growth 
factors, which sense soluble, ECM-, or proteoglycan-bound factors and interaction partners. Green 
symbols represent selected intracellular adapters to the actin cytoskeleton, as specified below the 
drawing (A and B); shaded labels represent major signaling molecules regulating actin organization and 
cell migration. Adapted from “ Friedl P et al (2011) Cancer invasion and the Microenvironment: 
plasticity and reciprocity. Cell”. 
 
Ena/VASP  
    The Ena/VASP family consists of Drosophila Ena, C. elegans Unc-34, Dictyostelium 
DdVASP, and the three mammalian family members VASP, Mena, and EVL (Ena-
VASP-like). All Ena/VASP family members share a conserved domain structure. An 
amino-terminal Ena/VASP homology 1 (EVH1) domain followed by a proline-rich 
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central region and a carboxy-terminal Ena/VASP homology 2 (EVH2) domain (Fig 4). 
 
 
Domain and functional organization of the Ena/VASP protein family 
The EVH1 domain belongs to the PH domain superfamily (Ball, 2000; Barzik, 2001). 
Unlike PH domains, EVH1 domains do not appear to bind to phosphatidylinositol 
lipids, although only PI(4,5)P2 has been tested (Volkman, 2002). Instead, the EVH1 
domain, similar to PTB domains (another branch of the PH domain superfamily), binds 
to peptide ligands with high affinity. EVH1 domains are also found in the WASP 
family, the Homer/Vesl family, and two other proteins, Spred and SMIF (Brakeman, 
1997; Callebaut, 2002; Callebaut, 1998; Gertler, 1996; Kato, 1997). Similar to WW and 
SH3 domains, the characterized EVH1 domains appear to bind to peptides containing a 
poly-proline II helix (PPII helix), a left-handed helix with three residues per turn (Ball, 
2000; Carl, 1999). Flanking residues in the vicinity of the PPII helix confer specificity 
of binding to SH3, WW, and EVH1 domains. The other EVH1 domains found in the 
Homer/Vesl and WASP protein families have binding specificities that differ from 
those of the Ena/VASP family (Barzik, 2001; Volkman, 2002). Functional binding sites 
for EVH1 domains are found in Zyxin, LPP, Vinculin, Fyb/SLAP, the Drosophila and 
C. elegans axon guidance receptor Robo/Sax-3, and in the ActA protein of Listeria 
monocytogenes (Bashawm, 2000). EVH1 domains recruit Ena/VASP proteins to 
specific sites within the cell.  
Following the EVH1 domain, Mena contains a long insertion not found in other 
Ena/VASP family members. This insertion in Mena is a striking five-amino acid long 
  
 
 
 
 26 
stretch of highly charged basic and acidic amino acids (LERER) that are repeated 14 
times. This repeat might adopt an extended helical structure that function as a protein-
protein-binding interface (Gertler, 1996). Mena’s Drosophila ortholog Ena contains a 
glutamine-rich insertion in the same relative part of the molecule with no known 
function. 
The central proline-rich region harbors binding sites for SH3 and WW domain–
containing proteins and the actin monomer-binding protein Profilin. This region is the 
most divergent within the family and therefore may have different binding partners and 
mechanisms of regulation. Ena binds to the SH3 domains of Abl, Src, and the carboxy-
terminal SH3 domain of Drk (Ahern-Djamali, 1999; Comer, 1998; Gertler, 1995). 
Similarly, EVL binds to the SH3 domains of Lyn, N-Src, Abl, and the WW domain of 
FE-65 (Lambrechts, 2000). In contrast, Mena does not bind to the SH3 domain of N-
Src, but is bound by the SH3 domain of IRSp53, Abl, Arg, Src, and the WW domain of 
FE65 (Ermekova, 1997; Gertler, 1996; Krugmann, 2001). It is not clear which of these 
interactions is physiologically significant and shared among all members of the 
Ena/VASP family. All Ena/VASP family members contain proline-rich-binding sites 
for the small G-actin-binding protein Profilin, and this binding is independent of their 
phosphorylation status (Ahern-Djamali, 1999; Gertler, 1996; Lambrechts, 2000). 
Profilin II, the major Profilin isoform expressed in brain tissues, binds as a dimer with 
high affinity to VASP but with low affinity to PI(4,5)P2. In contrast, Profilin I displays 
the opposite preferences (Jonckheere, 1999). 
The EVH2 domain of the Ena/VASP family harbors three conserved blocks: starting 
from the amino terminus, a G-actin-binding site, an F-actin-binding site, and a coiled-
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coil motif required for oligomerization (Bachmann, 1999; Gertler, 1996). The G-actin-
binding site resembles a motif in the small actin-monomerbinding protein ¯-thymosin 
(Gertler, 1996) and is required for the in vitro actin nucleation activity of VASP 
(Walders-Harbeck, 2002). The second conserved block in the EVH2 domain of VASP 
(259–276 aa in human VASP) can co-sediment and bundle F-actin at low salt 
conditions (Bachmann, 1999). The third conserved block (336–380 aa in human VASP) 
consists of a coiled-coil structure that mediates oligomerization of Ena/VASP proteins 
(Bachmann, 1999; Zimmermann, 2002). VASP behaves as a tetramer, and the coiled-
coil motif is sufficient to mediate tetramer formation (Bachmann, 1999; Zimmermann, 
2002)
 
Figure 4. Domain structure of Ena/VASP proteins. The EVH1 and EVH2 domains and proline-rich 
region are indicated. EVH1 mediates protein:protein interactions; most, but not all, EVH1 ligands bind 
to a motif that has the consensus sequence (D/E)FPPPPX(D/E)(D/E). The proline-rich region harbors 
binding sites for profilin,including a high-affinity site adjacent to the EVH2 domain. The EVH2 domain 
contains a G-actin-binding site (GAB), an F-actinbinding site (FAB) and a coiled-coil at the very C-
terminus that mediates tetramerization. Adapted from “Bear J et al (2009) Ena/VASP: towards resolving 
a pointed controversy at the barbed end. J Cell Sci”. 
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Function of Ena/VASP in cells and tissues 
Ena/VASP proteins are localized at actin cytoskeleton hot spots in the cell (the leading 
edge, filopodia tips, cell-substrate contacts, cell–cell contacts), and are additionally 
associated with the movement of several viral and bacterial pathogens, as well as 
objects mimicking these pathogens (reviewed in Krause, 2003).  
Filopodia, actin-rich, finger-like structures that protrude from the cell membrane of a 
variety of cell types, play important roles in cell migration, neurite outgrowth and 
wound healing (Mattila, 2008). Filopodia are characterized by a small number of long 
and parallel actin filaments that deform the cell membrane, giving rise to protrusions. In 
order for filaments to grow to the characteristic length observed in filopodia, capping 
proteins, specialized molecules that inhibit actin polymerization, need to be locally 
inhibited or sequestered and nucleation of new filaments needs to be favored. 
Furthermore, individual actin filaments are not sufficiently stiff to deform the cell 
membrane (Mogilner et al 2005). Proteins, such as VASP-family proteins are thought to 
be required to promote the initial transient association of actin filaments as they directly 
(Lebrand, 2004) or indirectly antagonize capping proteins (Breitsprecher, 2008), capture 
barbed ends (Pasic, 2008) and cross-link actin filament. Furthermore, they can act as 
processive filament elongators especially upon high-density clustering, at least in vitro 
(Breitsprecher, 2011). Actin filaments are then further stabilized by other crosslinkers, 
such as fascin, thus permitting the formation of bundles of sufficient stiffness to 
overcome buckling and membrane resilience (Vignjevic, 2006). 
Nevertheless, there is considerable controversy concerning the mode of action of 
Ena/VASP proteins and there is a partial convergence concerning only two points: 
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Ena/VASP proteins increase the protrusion of the leading edge, and the speed of 
propulsion of the bacteria Listeria monocytogenes and of objects like beads and 
droplets; and Ena/VASP decreases the frequency of actin filament branches formed by 
the Arp2/3 complex in actin networks in cells and on moving surfaces. Concerning the 
first point, the only note of caution appears to be associated with the behavior of whole 
cells: Moeller et al. (2004) see decreased overall cell motility when VASP is depleted 
from the leading edge of cells, whereas Bear et al. (2002) see the opposite. This is not 
particularly surprising given the complexity of processes at work for whole cell 
movement, and the fact that VASP is involved not only in leading edge dynamics, but 
in the formation of stress fi bers and cell-substrate adhesions. What is more important is 
that, in both cases, kymographs of protruding edge movement show more jagged 
profiles when VASP is present, supporting the general thesis that VASP promotes 
protrusion and propulsion. A similar result is observed in very different experimental 
conditions during repulsion from ephrin ligands (Evans, 2007). 
The knock-out mouse lacking individual members of Ena/VASP results in relatively 
minor phenotypes in mouse models (Aszodi, 1999), whereas the generation of triple 
null Ena/VASP mice reveal that Ena/VASP proteins have crucial roles in neuritogenesis 
and neural-tube closure (Kwiatkowski, 2007). Furman and collaborators (2007) 
demonstate also that mice lacking Ena/VASP proteins develop edema and hemorrhage, 
both resulting from disruption in endothelial barrier function, which lead to embryonic 
lethality, probably through a defect in actomiosin contraction in regions of cell-cell  
junction. 
 
  
 
 
 
 30 
Ena/VASP role in endothelia/epithelia 
In addition to its role in actin remodeling for cell motility, Ena/VASP is being 
increasingly implicated in cell–cell adhesion processes. Ena/VASP proteins localize 
with E-cadherin/catenin enriched puncta between primary keratinocytes (Vasioukhin, 
2000), and disruption of Ena/VASP function perturbs cadherin-associated actin bundles 
in CHO cells (Scott, 2006). In the developing Drosophila embryo, Ena is implicated in 
actin filament formation at apical adherens junctions between cells of the egg chamber 
(Baum and Perrimon, 2001). A study in Drosophila shows that Ena/VASP proteins are 
essential for epithelial zippering during dorsal closure (Gates, 2007), and the 
Ena/VASP-like protein in Xenopus seems to promote cell–cell adhesion during 
morphogenesis of the otic vesicle epithelium (Wanner and Miller, 2007). Along the 
same lines, Ena/VASP has been shown to be required for endothelial barrier function 
and correct embryogenesis in mice (Furman, 2007), and has been shown to stabilize cell 
– cell adhesion for a decrease in endothelial permeability in endothelial cells in culture 
(Benz, 2008). 
Endothelial cells line blood vessels and provide both a barrier function between blood 
and other tissue while still allowing immune cells access to the surrounding tissue. This 
barrier function is maintained through tightly controlled cell-cell adhesions and is 
positively regulated by PKA. Interestingly, PKA phosphorylates VASP at serine 157 
(Howe, 2002) following that phospho-VASP accumulate to cell-cell junctions and co-
immunoprecipitate with the tight-junction marker zonula-occludens-1 (ZO-1) protein 
from endothelial cells (Comerford, 2002). 
Similarly, by adhering to each other, epithelial cells form a physical boundary capable 
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of regulating the transfer of molecules across the epithelial sheet. This permits selective 
exchange of molecules between the organism and its environment, exemplified in the 
waste removal function of the kidney or nutrient uptake in the gut. In these systems 
Ena/VASP proteins localize to adherens junctions, and disruption of their function 
affects epithelial dynamics (Lawrence, 2002; Vasioukhin & Fuchs, 2001). Studies in 
Drosophila have demonstrated that reduction of either D-Abl or Ena affects epithelial 
morphology and epithelial sheet migration. Genetic interactions suggest that Ena 
functions in concert with components of the cadherin-catenin complex (which mediates 
cell-cell adhesion) and D-Abl in epithelial sheets at the adherens junction (Grevengoed, 
2001). In mammals, Ena/VASP proteins are found in epithelial contacts that are 
revealed as a double row of dot-like structures also containing F-actin, Cadherin, Zyxin, 
and Vinculin. These cell-cell contacts have been suggested to represent an early stage in 
cell-cell contact formation and have been termed the adhesion zipper (Vasioukhin, 
2000). It has been proposed that cell-cell contacts are generated after first contact of 
lamellipodia and/or filopodia of opposing cells (Ehrlich, 2002). Overexpression of a 
fragment of Ena/VASP responsible for oligomerization disrupts epithelial sheet 
formation (Vasioukhin, 2000). However, the specificity of this approach for Ena/VASP 
proteins has not been demonstrated. Although it seems likely that Ena/VASP proteins 
play an important role in epithelial dynamics, further work will be required to clarify 
their role in such processes. 
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Isoforms and spliced derived isoforms 
The Mena mRNA undergoes extensive alternative splicing to give rise to multiple 
protein isoforms that are expressed in specific tissues and cell-types (Gertler, 1996). By 
contrast, the EVL gene contains one alternatively spliced exon and VASP has none. 
There are 14 constitutively included exons in Mena mRNA and five alternatively 
spliced exons that can all encode protein sequence in frame. There has not been a 
comprehensive analysis of which of the possible combinations of alternatively included 
exons are actually produced as mRNA, nor do we know all of the cell types which 
produce the various Mena isoforms. 
At least four different isoforms of MENA has been described on Western blots of tissue 
extracts. The larger isoform of MENA, named +, presents a longer exon 6 which 
includes an extra 246 additional amino acids after the LERER repeats (Gertler, 1996; 
Urbanelli, 2006), and is expressed in developing and adult brain tissues (Lanier, 1999) 
and is tyrosine phosphorylated in vivo (Gertler, 1996). Some cDNAs containing the + 
exon may also contain two other small exons that introduce 4 and 19 aminoacids, right 
after the EVH1 domain, named ++ or +++ (or INV) (Gertler, 1996). Tani and 
colleagues described another  isoform, named MENA-s, expressed in spleen and in 
lymphoid cell lines (Tani, 2003). Nisticò’s group described another isoform named 
hMENA11a expressed in human epithelial cancer cell lines (Di Modugno, 2007; Pino, 
2008) and belonged to an epithelial splicing program driven in part by the activity of the 
splicing regulators ESRPs proteins (Warzhecha, 2009). 
The alternatively spliced 11a exon encodes 21 amino acids that are inserted into the 
EVH2 domain between the FAB sequence and the coiled-coil tetramerization domain. 
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The MENA paralog EVL also has an alternatively spliced 21 amino acid insertion 
(EVL-I) in a relative location identical to that of the 11a insertion site, but the sequences 
share no similarity (Lambrechts, 2000).  
 
 
Regulation of Ena/VASP 
Ena/VASP family members share each other for serine/threonine phosphorylation sites. 
VASP harbors three phosphorylation sites (Ser157, Ser239, Thr278), whereas Mena 
contains the first two, and EVL only the first site (Butt, 1994; Gertler, 1996; 
Lambrechts, 2000). Ser157 is located N-terminally of the central Proline rich region. 
Ser239 and Thr278 are within the EVH2 domain, adjacent to the G- and F-actin binding 
sites, respectively (Kwiatkowski, 2003). 
The mammalian Ena/VASP proteins are known substrates of cAMP and cGMP-
dependent serine and threonine kinases PKA, PKG, AMPK (Gertler, 1996; Lambrechts, 
2000). In vivo, Ser157 is preferentially phosphorylated by PKA, whereas Ser239 and 
Thr278 are targeted by PKG and AMPK respectively (Blume, 2007).  
These is a divergence between Ena protein in invetebrates and vertebrates: Drosophila 
Ena lacks a clear equivalent of VASP Ser157 (Gertler, 1996). When expressed in 
Ena/VASP-deficient cells, Ena localizes properly but fails to complement the 
hypermotility phenotype, possibly because it cannot be phosphorylated by PKA 
(Loureiro, 2002), suggesting that the basic molecular functions of the family have been 
conserved across evolution but that the vertebrate proteins may require additional 
regulation by PKA/PKG.  
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Ena/VASP can be phosphorylated in tyrosine as well. In fact, Ena was identified as 
target of Abl kinase in Drosophila (Gertler, 1995). Another difference between 
vertebrate and invertebrate Ena/VASP proteins is that the tyrosine phosphorylation sites 
in Ena are not conserved in the mammalian  Ena/VASP proteins. 
 
 
VASP phosphorylation effects 
Originally VASP was identified in platelets as a substrate for cyclic-nucleotide-
dependent protein kinases (Halbrugge, 1990). Its strategic position in important kinase-
driven signaling cascades established phospho-VASP as a marker for the integrity of 
cyclic-nucleotide-dependent pathways.  
Successively, it has been demonstrated a key role for this protein in many cellular 
processes such as actin dynamics, chemiotaxis, motility, cell-cell and cell-matrix 
adhesion (Howe, 2002; Lee and Chung, 2009; Worth, 2010). Despite its importance, the 
cellular function and complexity of VASP phosphorylation has remained uncertain. 
VASP phosphorylation is able to drive its subcellular localization; VASP Ser157 
accumulates at sites of high actin dynamics, at focal adhesion and at the cell periphery 
(Benz, 2008). Phosphorylation of VASP Ser239 and Thr378 has minor effect on the 
subcellular distribution of VASP. However, cell-type specific regulation of Ena/VASP 
proteins might exist because phosphorylation status of Ser239 modulates VASP 
localization in renal epithelial cells (Linsday, 2007). 
VASP goes to phosphorylation in response to microenviroment signals such as matrix 
associated protein (Collagen Type I, Fibronectin) or soluble factors (NO, IL-8) (Neel, 
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2009; Pula, 2006) .VASP is associated with actin filaments and focal adhesions, which 
form the interface between the cytoskeleton and the extracellular matrix. During cell 
detachment, VASP becomes heavily phosphorylated by PKA on Ser157, and is 
dephosphorylated transiently during reattachment to fibronectin (Howe, 2002). At focal 
adhesion VASP phosphorylation status regulates 1 integrin – RIAM/Talin complexes 
modulating cell speed migration (Worth, 2010). A study has shown that 
dephosphorylation of VASP at Ser157 may be required for the growth of adhesion 
strength during membrane retraction in microglia, which supports a role for VASP in 
regulation of integrin function (Lee and Chung, 2009). 
VASP phosphorylation is critical for its role in the architecture of the actin cytoskeleton 
during cell-cell junction formation in  epithelial (Vasiouckin, 2000; Quinlan, 2004; 
Scott, 2006) and endothelial cells (Benz, 2008; Hoelzle 2011). VASP Ser157 is 
enriched at focal adhesion and phosphorylation level decreased time-dependently when 
cells established cell–cell contacts (Benz, 2008). This fine regulation through 
phosphorylation can influence its protein-protein interaction and actin regulatory 
properties. It is known that binding of proteins to the EVH1 domain occurs 
independently of phosphorylation (Harbeck, 2000). In contrast, binding of certain SH3-
domain containing proteins to the proline-rich central region of Ena/VASP proteins is 
regulated by serine/threonine phosphorylation. VASP, when is not phosphorylated, 
forms complexes with different focal adhesion proteins such as nSrc (Lambrechts, 
2000), c-Abl in murine fibroblasts (Howe, 2002), -II-Spectrin in human endothelial 
cells (Benz, 2008), Integrin v3 in osteoclasts (Yaroslawkiy, 2005). On the other side, 
VASP phosphorylation is able to induce other interactions, such as PKA 
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phosphorylation of Ser157 is able to regulate integrin 1-Talin complexes in murine 
fibroblasts (Worth, 2010), or PKG phosphorylation of Ser239 is able to induce VASP-
CXCR2 interaction in neutrophils (Neel, 2009). 
The role of VASP in actin dynamics is in part influenced by its phosphorylation status. 
In fact, phosphorylation of VASP by PKA in vitro abolished VASP anti capping 
activity in the presence and absence of profilin and bundling formation (Barzik 2005), 
probably because of an negative charge over phosphates that can interfere with F-actin 
binding. The phosphorylation reduces the actin nucleating activity and F-actin-binding 
of VASP (Harbeck, 2000). In the EVH2 domain, the binding to G-actin is greatly 
reduced by phosphorylation of Ser239 (Walders-Harbeck, 2002). This phosphorylation 
site is conserved in Mena but absent in EVL, which points to differences among the 
family members in regard to their regulation (Gertler, 1996).  
Studies of mutant mice revealed that VASP is required for the PKA-mediated inhibition 
of platelet aggregation (Aszodi, 1999) suggesting that VASP is the critical PKA 
substrate required for this process, and that Ser157 may be the key site of regulation. 
 
 
MENA phosphorylation effects 
Most studies of MENA phosphorylation effects are been concetrated on tyrosine. First 
evidences in Drosophila demonstrated that Abl phosphorylates Ena during 
development. However, Ena may be phosphorylated by other tyrosine kinases (Gertler, 
1995). The phosphorylated tyrosine residues are clustered in the proline-rich region and 
it has been shown that the binding of the SH3 domain of Abl and Src to Ena is 
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abrogated when it is phosphorylated by D-Abl in vitro (Comer, 1998). One difference 
between vertebrate and invertebrate Ena/VASP proteins is that the tyrosine 
phosphorylation sites in Ena are not conserved in the mammalian Ena/VASP proteins, 
however human MENA is phosphorylated in Tyrosin 296 by c-Abl (Gertler, 1996; Tani, 
2003). 
MENA Tyr-296 is not conserved in VASP or EVL, raising the possibility that only 
MENA, but not EVL or VASP, is regulated by c-Abl. Tyr-296 in MENA is localized 
close to the proline-rich central region, as it is in Ena, suggesting that this 
phosphorylation could regulate binding of ligands to MENA. 
Few studies are been concentrated on serine phosphorylation effects. In random 
fibroblast migration, phosphorylation of MENA at its first phosphorylation site (Ser236, 
the equivalent of VASP Ser157) is essential for this function and MENA phospho-
mutant studies demonstrate that phosphorylation is not essential for its subcellular 
localization (Louireiro, 2002). 
The epithelial isoform hMENA11a is phosphorylated in response to EGF and NRG1 
stimulation and cooperates with the mitogenic HER2 activity in breast cancer cell lines 
(Di Modugno,  2007, 2010). The site of the 11a insertion is adjacent to the F- and G-
actin binding sites, and the 11a insertion can be phosphorylated, potentially disrupting 
actin binding. Therefore, it is possible that the 11a inclusion affects the way in which 
MENA interacts with barbed ends and adds an extra site for phosphoregulation of 
MENA function. 
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Potential Role of Ena/VASP during Tumor Formation and Metastasis  
MENA has several unique features not found in the other Ena/VASP proteins that 
endow it with the ability to potentiate carcinoma metastasis dramatically (Gertler & 
Condeelis 2011). Analysis of the invasion signature of murine mammary carcinoma 
cells revealed that MENA expression is upregulated in invasive cells compared to 
average primary tumor cells (Wang, 2004; Wyckoff, 2004). Robert Weinberg’s group 
found MENA upregulated in metastatic cells that also upregulated the transcription 
factor Twist (Yang, 2004). Increased MENA levels were also observed in invasive 
human breast cancers compared to normal mammary tissue (Di Modugno, 2004). In a 
cohort of breast cancer tissue samples a significant correlation among hMENA, 
epidermal growth factor receptor 2 (HER2) overexpression, the proliferation index 
(high Ki67), and phosphorylated Mitogen Associated Protein Kinase (MAPK) and AKT 
was found. Furthermore, the overexpression of hMENA/hMENA11a cooperated with 
Epidermal growth factor receptors family and downstream pathways to increase cell 
proliferation in breast cancer cell lines (Di Modugno 2007, 2010). In addition to breast 
cancer, MENA upregulation has been observed in advanced pancreatic, colon, gastric 
and cervical carcinomas (Pino, 2008; Gurtzu, 2009; Toyoda, 2009; Junilla 2010).  
It has been demonstrated that MENA alternative splicing generate isoforms with 
different biological function. In murine model, the comparison between stationary and 
invasive carcinoma cells revealed that the 11a exon is expressed in tumor cells making 
up the bulk of the primary tumor, but this exon is essentially undetectable in the mRNA 
from invasive tumor cells (Goswami, 2009). Consistent with this finding, in human the 
11a exon is specific to MENA isoforms expressed in tumor epithelial cell lines and is 
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not found in mesenchymal cells (Di Modugno, 2007; Pino, 2008). In fact, the 11a exon 
becomes excluded in human mammary epithelial cells that are driven to undergo EMT 
by expression of the EMT inducing transcription factor Twist (Warzecha, 2009). 
hMENA11a is also expressed in normal ovarian tissue where its inclusion is promoted by 
the Fox2 splicing factor (Venables, 2009). Interestingly, analysis of 21 aggressive 
ovarian tumors revealed a reduction in Fox2 levels compared to normal tissue and a 
concomitant loss of 11a inclusion in MENA (Venables, 2009). Therefore, MENA11a 
appears to be included in epithelial cell and primary carcinoma mRNA but is excluded 
in mesenchymal cells as well as in invasive/aggressive tumor cells. 
Recent findings suggest that expression of MENA classic, and MENA+++ (or MENA 
INV) in particular, promotes carcinoma cell invasion in 3D collagen gels and increases 
carcinoma cell motility in vivo (Philippar, 2008). MENA classic and MENA INV 
localize to and stabilize invadopodia, actin-rich protrusions required for degradation and 
movement through the extracellular matrix and possibly for invasion across basement 
membranes, thereby increasing the invasive and metastatic potential of tumor cells. 
MENA-INV expressing migratory carcinoma cells are highly sensitive to EGF in their 
protrusion and chemotaxis activities, leading to significantly enhanced in vivo invasion, 
whereas MENA11a expression is correlated with decreased EGF-induced in vivo 
invasionf(Roussos, 2011). Altogether, these findings demonstrate that hMENA may be 
a crucial axis of “druggable” signaling pathways leading to tumor cell invasion. 
Different from MENA, the contribution of VASP in tumor progression is still unknown. 
While its engagement in migration and membrane protrusion dynamics in normal cells 
is well-established, a similar role for VASP in cancer cells has not emerged. Dertsiz and 
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collagues in 2005 demonstrated lung adenocarcinomas had significantly greater VASP 
expression than normal epithelium and VASP expression increased significantly with 
more advanced tumour stage (Dertsiz, 2005). Recently in the same tumor model, it has 
been demonstrated that ribosomal S6 kinase 1 (RSK1) was reduced in metastatic versus 
primary lung cancer lesions and RSK1 is able to interact and phosphorylate VASP on 
Thr278, suggesting an anti-invasive role for phophorylated VASP (Lara, 2011). 
Another recent paper indicated a possible alteration of VASP phosphorylation and 
function in colorectal cancer, since Ser157 and Ser239 VASP phosphorylation were 
significantly reduced in colorectal adenocarcinomas compared to their normal 
counterparts (Zuzga, 2011). Furthermore, they demonstrated that VASP Ser239 
phosphorylation mediates arrest of invadopodia mediated proteolysis (Zuzga, 2011). 
 
 
Pancreatic ductal adenocarcinoma: an overview 
The pancreas is an organ that has endocrine and exocrine compartments. The endocrine 
compartment consists of α, β, δ, e, and pancreatic polypeptide cells organized into islets, 
whereas the exocrine compartment consists of acinar, ductal, and centroacinar cells. 
Acinar cells synthesize and secrete digestive enzymes, which are concentrated into a 
bicarbonate rich fluid that traverses through a complex network of ducts. The terminal, 
or intercalated, ducts are lined by flat, almost squamous-like epithelia. Terminal end 
duct cells that interface with acini are called centroacinar cells. Intercalated ducts merge 
to form intralobular ducts (lined by cuboidal epithelia), and these in turn merge to form 
interlobular ducts, which finally merge to form into the main duct (lined by simple 
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columnar epithelia) that traverses the pancreas to the duodenum, delivering fluid laden 
with digestive enzymes. 
Pancreatic cancer is one of the most dreaded of all cancers, having the highest case-
fatality rate of any major cancer. It is difficult to detect, early to metastasize, resistant to 
treatment and causes death with relatively little tumor burden.  The best hope for curing 
pancreatic cancer is early detection and surgery, although specialists focus on early 
detection because discovering pancreatic cancer at a stage when surgery can be 
performed only happens in a minority of all cases.  Chemotherapy has been shown to be 
of some help in treating pancreatic cancer, while radiation therapy is more controversial 
(reviewed in Hidalgo, 2010). The most common subtype of human pancreatic 
malignancy is Pancreatic Ductal AdenoCarcinoma (PDAC). This cancer originates in 
the ductal epithelium and evolves from premalignant lesions to fully invasive cancer. It 
has been established the most common neoplastic precursor to invasive adenocarcinoma 
of the pancreas is known as PanIN (pancreatic intraepithelial neoplasia) (Hruban, 2001; 
Maitra, 2006). There is a clear accumulation of genetic alterations associated with the 
histological progression from low-grade PanINs (PanIN-1) to intermediate grade 
PanINs (PanIN-2), to high-grade PanIN (PanIN-3), to invasive carcinoma. 
The molecular basis underlying the development of PDAC involves a number of diverse 
pathways and molecules. Data suggest that pancreatic cancer results from the successive 
accumulation of gene mutations (Li, 2004; Maitra, 2006). The four hallmark mutations 
implicated in PDAC (KRAS [>90%], p16INK4A [>90%], TP53 [70%], and SMAD4 
[55%]) have all been confirmed by genetically engineered mouse models in which 
targeted activation of Kras  with concomitant inactivation of Trp53 or Ink4A results in 
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the development of pancreatic cancer that is identical to the cognate human disease 
(Hingorani, 2005; Bardeesy, 2006). Almost all patients with fully established pancreatic 
cancer carry one or more of four genetic defects (Maitra, 2008).Oncogenic KRAS is 
known to stimulate cellular migration and permit survival in limiting nutrients, effects 
that may be accentuated when the wild-type Kras allele is lost as observed in metastases 
(Qiu, 2011). Deletion of the Ink4a locus in Kras mutant pancreatic cells promotes Notch 
and NF-kB signaling and metastasis in mouse models (reviewed in Mazur and Siveke, 
2011); likewise, point mutant TrP53 alleles possess novel properties that promote tissue 
invasion and metastasis by stimulating integrin/EGFR signaling (Muller, 2009). Finally, 
Smad4 loss promotes PDAC metastasis in mice (Mazur and Siveke, 2011), and SMAD4 
loss correlates with high metastatic burden clinically (Iacobuzio-Donahue, 2009).  
Characteristic of pancreatic cancer is the formation of a dense stroma termed a 
desmoplastic reaction (Chu, 2007; Mahadevan, 2007). The stroma is not just a 
mechanical barrier; rather, it constitutes a dynamic compartment that is critically 
involved in the process of tumor formation, progression, invasion, and metastasis (Chu 
2007; Mahadevan 2007). The pancreatic stellate cells (also known as myofibroblasts) 
play a critical role in the formation and turnover of the stroma. On activation by growth 
factors such as TGFβ1, platelet-derived growth factor (PDGF), and fibroblast growth 
factor, these cells secrete collagen and other components of the extracellular matrix; 
stellate cells also appear to be responsible for the poor vascularization that is 
characteristic of pancreatic cancer (Masamune, 2009). Furthermore, stellate cells 
regulate the reabsorption and turnover of the stroma, mainly through the production of 
matrix metalloproteinases (Zhang, 2007) and comigrate with PDAC cells to promote 
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metastasis in a transplantation model system (Xu, 2010).  
The role of angiogenesis in pancreatic cancer remains controversial. Although early 
data suggested that pancreatic cancer is angiogenesis dependent, as are most solid 
tumors, treatment with angiogenesis inhibitors has failed in patients with pancreatic 
cancer. A recent study in a mouse model showed that targeting the stromal hedgehog 
pathway increases tumor vascularization, resulting in increased delivery of 
chemotherapeutic agents to pancreatic tumors and greater efficacy (Olive, 2009).  
Inflammation has a well-established role in promoting tumor progression (Grivennikov, 
2010) and genetically engineered mouse models using mutant Kras support the notion 
that inflammation accelerates pancreatic carcinogenesis (Guerra 2007, 2011). In 
humans, chronic pancreatitis represents one of the highest risk factors for developing 
PDAC (Lowenfels, 1993). However, most PDAC patients do not have a history of 
chronic pancreatitis. PanIN lesions is associated with the appearance of an 
inflammatory stroma characterized by activated fibroblasts and myeloid-derived cells 
(Clark, 2007). Also, Inflammation is able to induce EMT even in low-grade PanINs that 
harbor only oncogenic Kras mutations, driving cell delamination from the glandular 
preneoplasm into the surrounding tissue and circulatory system (Rhim, 2012), 
suggesting that inflammation may promote cancer progression through two independent 
mechanisms: by facilitating changes in the microenvironment at the primary site of 
neoplasia and by facilitating invasion and dissemination by increasing cellular access to 
the circulation.  
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Figure 5. Components of Pancreatic Cancer. Pancreatic cancers are composed of several distinct 
elements, including pancreatic-cancer cells, pancreatic cancer stem cells and the tumor stroma. 
Pancreatic cancer is characterized by a dense, poorly vascularized stroma; this microenvironment 
contains a mixture of interacting cellular and noncellular elements. Autocrine and paracrine secretion of 
growth factors such as plateletderived growth factor (PDGF) and transforming growth factor β (TGF-β) 
and cytokines results in continuous interaction between the stromal and cancer cells. Pancreatic stellate 
cells are a key cellular element in the stroma. They are characterized by the expression of desmin, glial 
fibrillary acidic protein, and intracellular fat droplets. ALDH+ denotes aldehyde dehydrogenase, CTGF 
connective-tissue growth factor, CXCL-12 chemokine 12 ligand, EMSA electrophoretic mobilityshift 
assay, EMT epithelial-to-mesenchymal transition, FGF fibroblast growth factor, GTPase guanosine 
triphosphatase, HGF hepatocyte growth factor, HGF-met hepatocyte growth factor mesenchymal–
epithelial transition factor, JNK Jun N-terminal kinase, MMP matrix metalloproteinase, SPARC secreted 
protein, acidic, cysteine-rich, TIMP tissue inhibitor of MMP, TNF-α tumor necrosis factor α, and VEGF 
vascular endothelial growth factor. Adapted from “Hidalgo M (2010) Pancreatic cancer; NEJM”. 
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 Alternative splicing in cancer 
Alternative splicing is a key molecular event in the gene expression process, consisting 
in the recognition of exons and introns through sequences at the boundaries between 
them as well as on splicing regulatory sequences located within exons and introns. 
Splicing is a post-transcriptional process involved in the maturation of mRNAs and 
contributes to proteomic diversity. In fact, almost all human genes are susceptible to 
alternative splicing generating at least 10 times more mRNAs than genes (Blencowe BJ 
2006; Trapnell, 2010). This process is tightly regulated in a tissue- and cell-type 
dependent fashion (Matlin, 2005) and partecipates in different cellular program, 
including apoptosis, cell growth, angiogenesis, cell motility and EMT (Blencowe, 
2006). Aberration of splicing machinery results from mutations in splicing sites or 
dysfunction of splicing regulatory proteins (Licatalosi and Darnell, 2010) and this could 
occur during tumor initiation and progression, producing splicing variants expressed in 
cancer tissue compared to the normal counterpart and viceversa (Dutertre, 2010). A 
variety of cancer-associated genes express alternatively spliced isoforms (Srebrow, 
2006), indicating that regulation at the level of splicing may play important roles in 
cancer onset and progression. 
EMT is also likely regulated by post-transcriptional mechanisms including alternative 
pre-mRNA splicing. In human breast cancer, changes of fox-1 homologue (RBFOX) 
and epithelial splicing regulatory proteins (ESRPs) families of splicing regulator are 
found (Shapiro, 2011; Horiguchi, 2011). Warzecha and collaborators demonstrated that  
ESRPs are components of an epithelial genes signature and demonstrated a 
downregulation of these proteins in cells that undergo EMT (Warzecha, 2009). ESRP 
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splicing program regulates epithelial and mesenchymal variants of FGF receptors 2 
(FGFR2), CD44, ENAH, P120-catenin and other many genese with functions in cell-
cell adhesion, migration and cytoskeletal dynamics, all processes involved to 
phenotypic changes that occur during EMT. Horiguchi and collaborators demonstrated 
also that ESRPs proteins are downregulated during TGF mediated EMT in breast and 
pancreatic cancer cell lines, linking alternative splicing with EMT (Horiguchi, 2011). 
Alternative splicing permits the generation of protein isoforms having different 
biological activities, for example, the splicing of fgfr-2 genes generated spliced variants 
with distinct FGF-binding specifities and ESRPs proteins activate the splicing of exon 
IIIb and silence the splicing of exon IIIc leading to alternatively variants expression in 
epithelial and mesenchymal cells (Warzecha 2009,2010). 
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Outline of the PhD thesys 
    My PhD thesis aims to shed light on hMENA splicing program deregulated in cancer, 
focusing on pancreatic adenocarcinoma. In particular, my work links hMENA splicing 
program altered in PDAC with the well known role that Ena/VASP proteins have in cell 
adhesion and migration, processes frequently altered during cancer progression and 
metastatic events. 
Previous and recent results shown that splicing regulatory factors, which process 
numerous genes regulating biological processes such as cell morphology, adhesion, 
migration, and proliferation,  are altered in ovarian, prostatic, breast and pancreatic 
cancer (Venables, 2009; Warzecha, 2010; Shapiro, 2011). A variety of cancer-
associated genes, among them hMENA, express alternatively spliced isoforms, 
indicating that regulation at the level of splicing may play important roles in cancer 
onset and progression. 
Based on these findings, this thesis aims to evaluate whether hMENA alternative 
isoform expression observed in breast cancer, occurs also in PDAC. Futhermore, since 
Ena/VASP proteins play an important role in epithelial dynamics, cell – cell junction 
formation and cell invasion (Vasiouckin, 2000; Ehrlich, 2002; Loureiro, 2002), this 
thesis focuses on hMENA alternative isoform expression potential role in cell-matrix 
adhesion and cell invasion. 
Our group has characterized three hMENA isoforms, one 88-kDa unspliced isoform 
defined as “classic” and two splice variants, named hMENA11a and hMENAv6. The 
first (90 kDa) characterizes epithelial cancer cell lines expressing E-Cadherin, whereas 
the latter (80 kDa) is expressed in breast and cervix tumor cell lines displaying the 
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phenotypic features of EMT with migratory behaviour.  
Differently from the breast model, where hMENA is not expressed in normal 
epithelium but overexpressed following transformation and tumor progression, hMENA 
and hMENA11a are co-expressed in normal pancreas whereas primary tumors lack the 
expression of the epithelial hMENA11a isoform, in line with recent results indicating 
that hMENA splicing may be altered in pancreatic tumor progression (Horiguchi, 2011). 
Western Blot analysis of pancreatic cell lines evidence an alternative expression of 
hMENA isoforms. hMENA11a is expressed in the normal human pancreatic ductal 
epithelial cell line (HPDE) besides epithelial pancreatic tumor cell lines (CFPAC, 
T3M4, and PACA44), whereas hMENAv6 is expressed in PANC1 cells that lack the 
epithelial isoform hMENA11a and express VIMENTIN. 
Epithelial cells express one or more of the Ena/VASP proteins, and these in turn 
localize to the leading edges of lamellipodia, the tips of filopodia, focal adhesions, cell–
cell junctions, suggesting that Ena/VASP proteins may be important regulators of actin 
dynamics in epithelia.  
Starting from the knowledge that the phospho-VASP is absent in resting monolayers, 
we tested all cell lines grown at sub-confluence after 48h of reattachament and we 
observe that VASP is more phosphorylated at Ser-157 either in normal or pancreatic 
cancer cell lines with an epithelial phenotype and expressing hMENA11a, whereas we 
don’t observe an appreciate level of P-Ser157 in the hMENA11a negative/hMENAv6 
positive PANC1 cell line.  
Further evidences indicate that Ser157 VASP phosphorylation is mediated by PKA, 
observed in hMENA11a expressing cells respect than hMENA11a negative cells when 
  
 
 
 
 49 
cell-cell contacts are yet stabilized. Specific silencing of hMENA11a isoform in HPDE 
cells determines a significant reduction of P-Ser157 VASP level. Furthermore, confocal 
analysis of HPDE cells demonstrate P-Ser157 VASP and hMENA11a co-localize at focal 
adhesion and the co-localization is maximum when PKA is activated. On the contrary, 
in PANC1 (hMENA11a negative) cells, Ser157 VASP is not phosphorylated when cell-
cell contacts are stabilized. The transfection of hMENA11a isoform in PANC1 cells 
rescues either P-Ser157 VASP level or P-Ser157 VASP co-localization with hMENA11a 
at focal adhesion.  
We also investigated ESRPs proteins which are a component of an epithelial gene 
signature and the downregulation of the ESRPs in cells that undergo EMT corresponded 
with switches in splicing of several ESRP-regulated exons, among them hMENA. We 
focused on hMENA splicing impaired in PANC1 cells, transfecting ESRP1 cDNA in 
these cells. The resulting expression of hMENA11a determine an increase of P-Ser157 
VASP signal, an increase of adhesive properties to different matrix-derived components 
and a reduction of cell invasive capabilities.  
Altogheter, our results demonstrate that hMENA splicing is a critical step in cancer and 
the lost of epithelial hMENA11a isoform strongly contributes to the aggressivness of this 
incurable neoplasia. 
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Reagents and antibodies production 
 
The mouse monoclonal antibody (IgG1) specific for the hMENA11a isoform was 
developed against a 18-aa peptide (RDSPRKNQIVFDNRSYDS) belonging to the 11a 
exon, purified and employed for WB, immunohistochemistry and confocal analysis. To 
obtain antibodies specific to the hMENAv6 isoform, rabbits were immunized with a 
peptide coded by a region covering the 5 and 7 exon junction (NH2-ERRISSAGIVLG-
COOH). The rabbit antiserum was then purified by two-step affinity chromatography 
using peptides coded by the 5 and 6 exon junction or by the 6 and 7 exon junction 
(EWERERRISSAAA and SQQGIVLGPLAPP) in order to deplete the serum from the 
antibodies recognizing regions common to all the hMENA isoforms. The specific IgGs 
were then purified using the immunogenic peptide (ERRISSAGIVLG) by affinity 
chromatography (Di Modugno, paper submitted).  
H89 and Forskolin were purchased from Sigma.  
 
 
 
Cell lines 
The following cell lines were purchased from the American Type Culture Collection: 
CFPAC, PANC1. The T3M4, PACA44, and PT45 cell lines were kindly provided by 
Dr. F. Velotti (Tuscia University, Viterbo, Italy). The normal human pancreatic ductal 
cell line (HPDE) was kindly provided by Dr. P. Allavena (Humanitas Fundation, 
Milano, Italy). All cell lines were maintained in RPMI 1640 (Life Technologies, Inc.). 
The medium was supplemented with 10% fetal bovine serum (Life Technologies) and 
L-glutamine (Bio Whittaker).  
To correlate VASP phosphorylation with cell density, all cell lines tested were detached 
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with trypsin-EDTA and collected into culture medium. Cells were seeded on tissue 
culture plates  for 48h before lysis and analysis by Western blotting. 
 
RT-PCR 
hMENA splice variants were detected by RT-PCR using MTC1f and MTC4r primers as 
reported (Di Modugno, 2007). PCR products were analyzed on a 1% agarose gel 
electrophoresis and ethidium bromide staining. 
 
In vitro Transcription-coupled Translation 
The in vitro translation of the hMENA11a, hMENA and hMENAv6
 
cDNA (inserted into 
the pcDNA3.1 vector) was examined in an in vitro transcription-coupled translation 
system following the manufacture’s instruction (TNT, rabbit reticulocyte lysate system, 
Promega Corporation).  
 
3D cultures 
HMT-3522 cell lines (S1, S2, T4-2) were cultured in conventional tissue culture 
polystyrene and in 3D assays using growth factor reduced reconstituted basement 
membrane (Matrigel; BD), according to previously described methods (3, 4). Briefly, 
S2 and T4-2 cells were maintained on flasks coated with acid extracted collagen type I 
(PureCol; Advanced BioMatrix), while for 3D assays, cells were cultured on a thin 
layer of polymerized Matrigel for 4 days in the presence of growth media containing 
5% lrECM or pharmacological inhibitors. For growth factor depletion, EGF was 
removed from S1 cultures 24h prior to extraction from lrECM. Each lot of 
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pharmacological inhibitors and lrECM used in the study were carefully validated prior 
to use in experiments 
 
Transfections, Small-interfering RNA treatment and  hMENA11a/ESRP1 transduction 
The hMENA11a–pMSCV, pMXs-IRES-blast2 Esrp1-FF and pMXs-IRES-blast2 
retroviral transductions were performed using the 293T packaging cell line. Cells were 
transduced in T25 flasks with 5g of the retroviral expression vector, 1,25 g of 
pCMV-VSV-G and 3,25 g of Gag-Pol using LipofectAMINE 2000. After 5 hr, the 
media was replaced with fresh DMEM with 5% FBS, and virus was harvested after an 
additional 24 hr. Target cells in exponential growth phase were plated in 6-well plates at 
a density of 3x105 cells/well and were transduced with a 50/50 mix of viral supernatant 
and growth media. Selection was carried out using 10 g/ml blasticidin (for ESRP 
transduction) or 500 g/ml of G418 (for hMENA11a transduction) in complete culture 
medium. 
Specific 11a exon silencing was achieved by transfecting cells with a mix of three 
siRNAs, each matching 21 nucleotides within the 11a exon sequence; highly functional 
siRNA sequences were selected using siDirect 2.0 web server, that provides efficient 
and target-specific siRNA design for mammalian RNAi.  
Mutants of hMENA11a were obtained by the use of QuikChange II Kit (Qiagen), 
following the manufacturer instruction. The primers used were designed to present the 
substitution of the codons corresponding to two Ser (TCT and TCA) of the 11a exon, 
with codons (GCT and GCA) encoding Alanine.  PCR products were cloned into 
pcDNA3.1 vectors and sequenced. 
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Western blot (WB) analysis and Immunoprecipitation (IP) 
Cells were lysed for 30 min at 4°C in 10% glycerol, 0.1% SDS, 0.5% DOC, 1% NP-40 
in PBS containing protease and phosphatase-inhibitors. Lysates were centrifuged and 
protein quantification of supernatants was determined using BCA Protein Assay 
Reagent (Pierce, Rockford, IL, USA). Lysates (50 µg) were resolved on 10% 
polyacrylamide gel and transferred to nitrocellulose membrane (GE-Healthcare, Little 
Chalfont, UK). Blots were blocked for 1 h with 3% skimmed milk in TBST and probed 
in 3% skimmed milk/TBST overnight at 4°C with the following antibodies: 10 µg/ml 
anti-hMENA rabbit CKLK1 (pan-hMENA) antibody; 1 µg/ml anti-hMENA11a mouse 
monoclonal antibody; anti-hMENAv6 (0,6g/ml); mouse anti-E-CADHERIN from 
BD Biosciences (San Jose, CA); mouse anti-N-CADHERIN from DakoCytomation 
(Glostrup, Denmark) VASP Ab from BD bioscience (USA); P-Ser157 VASP and P-
Ser239 VASP Abs  from Nanotools (Germany). 
After 3 washes of 15 min each, blots were incubated with the appropriate secondary 
antibody conjugated with HRP for 1 h and then washed again three times. The protein 
signals were detected by ECL kit (GE-Healthcare). For actin signal, blots were reprobed 
with 1 µg/ml monoclonal anti-actin, mouse-ascites fluid clone AC-40 (Sigma Aldrich, 
Poole, UK). X-ray films were scanned by HP Scanjet 5470 and processed by Corel 
Photo Paint 12. 
Immunoprecipitation experiments were carried out using Pierce Crosslink IP kit 
(Thermoscientific, Rockford, USA), following the manufacturer Instruction,  with Pan-
hMENA CKLK1 rabbit Ab (Di Modugno et al. 2007); hMENA11a rabbit Ab and pre-
immune rabbit IgG as negative control. 
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Two-Dimensional Electrophoresis (2DE) 
Cells were washed extensively with PBS, pellets lyophilized and solubilized with 2DE 
solubilization buffer (9 M Urea, 10 mM Tris, 4% CHAPS, 65 mM DTT, 2% IPG buffer 
ampholine pH 3-10, protease inhibitor cocktail). Protein samples (200 µg) were applied 
to 7 cm IPGstrips pH 3-10NL (GE-Healthcare) by in-gel rehydration. Iso-electro 
Focusing (IEF) was performed with an IPGphor system (GE-Healthcare) following a 
standard protocol as described (Conti, 2005). Strips were equilibrated in 50 mM pH 8.8 
Tris-HCl buffer containing 6 M urea, 30% glycerol, 2% SDS and 2% DTT, followed by 
an incubation in the same buffer replacing DTT with 2.5% iodoacetamide. The strips 
were loaded on the top of 10% acrylamide SDS-PAGE gels for the second dimension 
separation. Proteins were electrontransferred onto nitrocellulose membranes and 
Western blot performed as described above. Images were acquired at high resolution 
and 2D immunoreactivity patterns analyzed using Progenesis PG240 v2005 software 
(Nonlinear dynamics, Newcastle, UK). Relative molecular mass (Mr) were estimated by 
comparison with Mr reference markers (Precision, Bio-Rad, Hercules, CA, USA) and 
isoelectric point (pI) values assigned to detected spots by calibration as described in the 
GE-Healthcare guidelines. 
 
 
Confocal microscopy and image analysis 
Cells were cultured in individual wells of a 24-well plate. Cells were fixed in modified 
paraformaldehyde fixative (60mM PIPES, 25mM HEPES, 10mM EGTA, 2mM MgCl2, 
120mM sucrose, 4% paraformaldeyde; final pH 7.4) for 15 minutes at room 
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temperature. Cells were incubated with P-Ser157 VASP (Cell Signaling) at dilution 
1:100, or with hMENA11a mouse monoclonal antibody at dilution 1:50 or pan-hMENA 
antibody (gently provided from Gertler’s Lab) at dilution 1:1000, and were stained 
using AlexaFluor594-conjugated, AlexaFluor488-conjugated antibody, and DAPI 
(Invitrogen). 
Fixed and stained cells were imaged using a Zeiss 710 laser scanning microscope under 
63x Plan Apochromat (1.4 numeric aperture) oil immersion lens with Zen 2008 imaging 
software (Zeiss).  
 
 
Adhesion Assays 
Adhesion assays were performed using plates (96 well) pre-coated with collagen I, 
collagen IV, fibronectin (BD, Biosciences) or with 1% bovine serum albumin as the 
control. Cells were harvested with trypsin/EDTA and resuspended in 2% FCS medium. 
0,1 ml cells suspension were allowed to attach at 37 °C for 1,5 or 3 h. Unbound cells 
were removed by washing twice with phosphate-buffered saline. Attached cells were 
fixed in 96% ethanol at room temperature for 10’, stained with 0,1 % crystal violet for 
30’, then resuspended in 0,2% TritonX in dH20 to lyse cells and read absorbance at 570 
nm. Each experiment was reproduced three times. 
 
Cell invasion assay 
Cells were counted and equal numbers (50.000) were seeded in Matrigel invasion 
chamber (24 wells; BD Biocoat Matrigel invasion chamber, BD Biosciences) in 
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duplicate following the manufacturer’s instruction. Cells were allowed to invade for 
24h, then were stained, photographed and at least 10 fields were counted. Each 
experiment was performed three times. 
 
 
Patients and tissue specimens  
A series of 26 patients (median age, 62 y; range 39-78 y) who underwent pancreatic 
resection or biopsy at the Regina Elena National Cancer Institute between 2002 and 
2005 with a diagnosis of pancreatic adenocarcinoma were retrospectively collected for 
immunohistochemical studies. This series included 12 primary (9 stage II, 1 stage III, 
and 2 stage IV) and 14 metastatic carcinomas (11 liver metastasis and 3 other 
abdominal sites). Tumors were staged according to the Unione Internationale Contre le 
Cancer TNM System 2002 and collected according to the Internal Ethic Committee 
guidelines. 
 
 
Immunohistochemistry  
Pancreatic cancer specimens were fixed for 18 to 24 h in buffered formaldehyde and 
then processed through to paraffin wax. hMENA expression was evaluated by 
immunohistochemistry using the monoclonal antibody clone 21 (BD Transduction; 2.5 
μg/mL) that recognizes all the hMENA isoforms and does not crossreact with other 
members of Ena/VASP family proteins (Di Modugno, 2006). hMENA11a was revealed 
using the anti-hMENA11a specific mAb  described above.  Dewaxing, antigen retrieval, 
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incubation with the primary antibody, chromogenic reaction with 3,3′-
diaminobenzidine, and counterstaining with Mayer Haematoxylin were done with an 
automatic autostainer (Vysion Biosystems Bond; Menarini). Sections were mounted in 
aqueous mounting medium (Glycergel; DakoCytomation). The intensity of hMENA 
staining, detected in the cytoplasm, was scored from 0 to 3+ according to the following 
criteria: no staining, score 0; weak cytoplasmic staining of neoplastic cells, score 1+; 
moderate cytoplasmic staining, score 2+; and strong cytoplasmic staining, score 3+. 
Evaluation of the immunohistochemical data was done independently and in blinded 
manner by two investigators. 
 
 
Statistical analysis 
All experiments were repeated at least twice. Statistical significance was determined by 
Student's t test (two tailed) comparison between two groups of data. Asterisks indicate 
significant differences of experimental groups compared with the corresponding control 
condition. Statistical analysis was done using GraphPad Prism 4, V4.03 software 
(GraphPad, Inc.). Change in the phosphorylation status by 2DE was evaluated, using 
Progenesis v.2004 software (Nonlinear Dynamics), by absorbance indicated as 
normalized spot volume. Normalization was done by multiplying the total spot volume 
by the constant factor 100, which produces spot percentage volume. Densitometric 
quantitation of hMENA immunoreactivity was determined by ImageJ and normalized in 
comparison with the actin immunoreactivity. 
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hMENA splicing program generates isoforms differently expressed in epithelial and 
mesenchymal cells 
To characterize hMENA splicing variants relevant to breast cancer progression, we 
performed hMENA transcript synthesis and cDNA sequencing using hMENA-specific 
primers in the breast cancer cell line MDA-MB-231. Using this method, in addition to 
the sequence of hMENA (1713nt), we were able to identify a new sequence of 1602 
nucleotides from the ATG to the stop codon. We named this hMENA isoform 
hMENAv6 (GenBank, Accession: EU255274) since it lacks the internal exon 6 of 111 
nucleotides (Fig 6 A-B). hMENAv6 cDNA encodes a protein of 533aa lacking a 37aa 
internal peptide located between the LERER and the Proline-rich region of hMENA 
(Fig 6 A). The absence of this peptide brings the LERER domain and PKA Ser 
phosphorylation site (Ser 236 in mice) with the proline-rich domain closer together (Fig 
6 B). The WB analysis of hMENA11a- (hMENA11a variant includes an exon absent in 
hMENA), hMENA-, and hMENAv6- in vitro translated proteins, using an antibody, 
which recognizes all hMENA isoforms (pan-hMENA), showed that the proteins migrate 
with apparent molecular weights of 90kDa (hMENA11a), 88kDa (hMENA) and 80kDa 
(hMENAv6) (Fig 6 C). The two in vitro translated hMENA and hMENAv6 isoforms 
appear to correspond to the bands revealed by WB analysis in MDA-MB-231 tumour 
cell protein extracts (Fig 6 C). RT-PCR experiments performed on SBT and MDA-MB-
231, the breast cancer cell lines we used to clone hMENA11a and hMENAv6 
respectively, revealed that, hMENA was expressed in both. Differently, hMENA11a was 
expressed only in the luminal breast cancer cell line SBT, whereas hMENAv6 only in 
  
 
 
 
 61 
the basal  MDA-MB-231 (Fig 6 D).   
We previously showed that hMENA is absent in normal breast tissue, but becomes 
expressed in high-risk benign lesions and invasive tumors, suggesting that hMENA 
expression could be an early marker of breast tumorigenesis (Di Modugno, 2006). We 
therefore turned to the HMT-3522 isogenic cell strain series, a novel model of human 
breast cancer progression where no oncogenes were used for transformation (Rizki, 
2008), to ask whether hMENA alternative splicing is linked to malignant progression. 
In three-dimensional laminin-rich gel assays (3D lrECM) (Petersen, 1992), we found 
that non-malignant HMT-3522-S1 mammary epithelial cells do not express hMENA11a 
unless treated with EGF, whereas the premalignant HMT-3522-S2 cells, which have 
autocrine EGFR signalling (Madsen, 1992), express hMENA11a (Fig 7 A). The 
tumorigenic and invasive, but not metastatic, HMT-3522-T4-2 cells express both the 
hMENA11a and hMENAv6 isoforms. Targeting the EGFR, MAPK, or PI3K signalling 
in HMT-3522-T4-2 cells using small molecule inhibitors, (AG1478, PD98059, or 
LY294002, respectively) or using an anti-EGFR function blocking antibody, mAb-225 
‘reverts’ the phenotype of these cells from malignant to non-malignant by restoring 
apicobasal polarity and inducing growth arrest in 3D lrECM. We found that reversion 
leads to concurrent down-regulation of two hMENA isoforms (Fig 7 A). These data 
suggest that polarized and growth-arrested cellular architecture correlates inversely with 
hMENA expression. 
We asked whether expression of hMENA11a and hMENAv6 isoforms correlates with 
either epithelial or mesenchymal markers in a panel of breast cancer cell lines. With the 
exception of DAL cells, we found that all E-CADHERIN positive cell lines express 
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hMENA11a (Fig. 7 B). However, hMENA11a expression was independent of functional 
E-CADHERIN since SKBr3 cells, which have a mutation in the E-CADHERIN gene, 
retained hMENA11a expression. On the other hand, absence of hMENA11a expression 
correlated with the expression of hMENAv6, absence of E-CADHERIN and the 
presence of N-CADHERIN. This pattern of hMENA isoform expression is found also 
in cervix cancer cell lines (C33A and SiHa) (Fig. 7B) 
            
Figure 6. (A) Diagrammatic representation of hMENA splice variants. (B) hMENA protein domains. 
Asterisks indicate Ser phosphorylation sites. GAB and FAB correspond to the G actin and F-actin 
binding sites, respectively. Sites of V6 and 11a peptides are indicated by arrows. Sequence of peptide V6, 
absent in hMENAv6 isoform, is reported. (C) In vitro translated hMENA11a, hMENA and hMENAv6 
analyzed by WB analysis using the pan-hMENA Ab (10g/ml). Cell lysates (30g) of SBT and MDA-MB-
231 breast cancer cell lines (used to obtain hMENA11a and hMENAv6 cDNAs respectively) were also 
tested by WB to identify the corresponding in vitro translated protein bands. (D) RT-PCR performed with 
primers (MTC1f and MTC4r) flanking the region of alternative splicing on MDA-MB-231 and SBT RNA. 
PCR experiment was also done on the pcDNA3.1 vectors containing the three hMENA variants. PCR 
products were analyzed by agarose gel electrophoresis and ethidium bromide staining.  
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Figure 7. (A) hMENA isoform expression in a 3D model of breast cancer progression. The WB analysis 
of lysates of 3D grown HMT-3522 S1, S2 and T4-2 progression series cells with hMENA isoform specific 
antibodies is shown. S1 cells grown for 24h in growth medium depleted of EGF (S1) do not express 
hMENA11a  isoform, which is expressed in the presence of EGF. WB analysis of T4-2 cells and T4-2 cells 
reverted with AG1478, mAb225, LY294002 and PD98059 treatments, showing a strong reduction of 
hMENA isoform expression following the reversion of the transformed phenotype. 2D grown SKBr3 (*) 
cell lysate is reported as a control of hMENA11a expression. (B) WB analysis of lysates of breast and 
cervix tumor cell lines with hMENA isoform specific antibodies, anti E-CADHERIN and N-CADHERIN 
antibodies, indicating a strong correlation between hMENA11a and E-CADHERIN as well as between 
hMENAv6 and N-CADHERIN expression. 
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hMENA11a and hMENAv6 spliced isoforms correlates with an epithelial and a 
mesenchymal phenotype in normal and pancreatic cancer cells  
We previously found that hMENA11a is associated with pancreatic cancer cell lines with 
an epithelial phenotype and identifies EGFR-dependent cell lines that are sensitive to 
the EGFR inhibitor erlotinib (Pino, 2008). To investigate whether hMENA11a and 
hMENAv6 expression correlates with epithelial and mesenchymal markers, we 
analysed by WB five pancreatic tumor cell lines and one normal cell line. hMENAv6 
is expressed together with hMENA in PANC1 cells that lack hMENA11a and express 
VIMENTIN (Fig 8). hMENA11a, together with E-CADHERIN, is expressed in epithelial 
pancreatic cell lines (CFPAC, T3M4, and PACA44) and in the normal human 
pancreatic ductal epithelial cell line (HPDE), whereas it was undetectable in 
mesenchymal PT45 and PANC1 pancreatic cancer cell lines, as previously reported 
(Pino, 2008).  
                          
Figure 8. WB analysis of lysates of normal and tumor pancreatic cell lines. Cells were cultured at 
sub-confluence for 48h before scraped and lysed. Lysates were analyzed with antibodies against 
hMENA11a, hMENAv6, pan-hMENA, E-CADHERIN, VIMENTIN and ACTIN. 
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hMENA11a correlates with an epithelial phenotype and VASP phosphorylation at Ser157 
in normal and pancreatic cancer cells  
hMENA belongs to Ena/VASP protein family, which members are able to tetramerize 
and act sinergistically (Gertler, 1996; Krause, 2003). VASP, the other member of the 
family, undergoes phosphorylation in different serine/threonine residues, which are 
critical for the role exerted by this protein in the architecture of the actin cytoskeleton 
during cell-cell adhesion in epithelial cells (Vasioukhin, 2000; Quinlan, 2004; Scott, 
2006). Thus we investigated whether VASP phosphorylation status may be related to 
the hMENA splicing program. The results of WB analysis evidence that the Ser157 is 
more phosphorylated in normal and pancreatic cancer cells with an epithelial 
phenotype, hMENA11a positive and hMENAv6 negative with respect to the cells 
hMENAv6 positive and hMENA11a negative (Fig 9). The phosphorylation of VASP at 
Ser157 induces a shift in the electrophoretic mobility of VASP protein (Howe, 2002).                        
In line with the data obtained with the phospho-VASP Ab, the analysis with VASP Ab 
reveals that phosphorylated VASP (upper band) is more expressed in hMENA11a 
positive cells, whereas the not-phosphorylated VASP (lower band) shows a comparable 
expression among the cell lines (Fig 9, lower panel). The phosphorylation status of 
Ser239 is unchanged among the cell lines evaluated. 
Since after the formation of cell–cell contacts, VASP is strongly de-phosphorylated 
(Howe, 2002; Benz, 2008), the biochemical experiments have been perfomed in cells 
grown at sub-confluence and scraped after 48h of reattachment before analysis.  
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Figure 9. WB analysis of lysates of normal and tumor pancreatic cell lines. Cells were cultured at sub-
confluence for 48h before scraped and lysed. Lysates were analyzed with antibodies against hMENA11a, 
VASP or the phosphorylated form of ser157 VASP and ACTIN. 
 
 
hMENA11a enhances VASP phosphorylation at Ser 157  
Reasoning that the invasive PANC1 cancer cell line does express neither hMENA11a nor 
P-Ser157 VASP, whereas the normal HPDE express both the proteins, we performed 
experiments of gain and loss of function to identify the influence of hMENA11a isoform 
on VASP phosphorylation. A specific knock-down of hMENA11a isoform by si-RNA 
evidences that the  down-regulation of  hMENA11a resulted in a reduction of 
phosphorylation of VASP at Ser157 in HPDE cells (Fig. 10 A), thus suggesting a link 
between hMENA11a expression and P-Ser157 VASP.  
Then, we studied the influence of hMENA11a on VASP phosphorylation status in 
invasive PANC1 hMENA11a negative cells. We stably transduced hMENA11a isoform in 
PANC1 cells and By sub-cloning we produced and characterize PANC1- hMENA11a 
clones. Three representative clones with different levels of hMENA11a and hMENAv6 
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are shown in Figure 10 panel B. Clone 13 shows the lowest level of hMENAv6 and 
the highest level of hMENA11a and P-Ser157 VASP. A strong correlation between 
hMENA11a and P-Ser157 VASP is evident suggesting that the presence of hMENA11a 
enhances VASP phosphorylation at Ser157. This is confirmed by experiments of 
silencing of hMENA11a in PANC1-hMENA11a (clone 13) where a strong reduction of P-
Ser157 VASP is observed in hMENA11a silenced cells (Fig 10 C).  
To confirm the data obtained by WB analysis, we studied the pattern of VASP post-
translational modifications in pancreatic cells by 2D-electrophoresis analysis. We found 
that VASP signal in PANC1-hMENA11a protein lysates, consists of four spots, two of 
them also revelead by the P-Ser157 VASP Ab (Fig 10 D). In HPDE and PANC1-
hMENA11a protein lysates the spots revealed by VASP Ab show a more pronounced 
shift toward lower pH with respect to control PANC1 cells, suggesting a higher level of 
phosphorylated VASP (Fig 10E).  
Previous data from our group demonstrated that hMENA11a undergoes phosphorylation 
following growth factors cell stimulation, and the 21 aa of the 11a peptide contains two 
putative serine sites of phosphorylation (Fig 11 A; Di Modugno, 2007). To explore the 
relevance of hMENA11a phosphorylation in modulating the phosphorylation of VASP, 
we have mutated the two serine, present in the 11a peptide, to alanine. Mutant 
hMENA11a transduction in PANC1 cells does not induce Ser157 VASP phosphorylation 
differently from wild type hMENA11a transduction (Fig 11 B), suggesting that 
hMENA11a should be phosphorylated to exert its effect on VASP phosphorylation.  
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Figure 10. (A) WB analysis of HPDE cells transduced with the empty vector (CNTR) or with specific 
siRNA targeting hMENA11a, using antibodies against VASP, the phosphorylated form of ser157 VASP, 
hMENA11a or ACTIN. 
(B) WB analysis of lysates of PANC1 cells transduced with empty vector (CNTR) or with hMENA11a. After 
transduction and selection with antibiotic geneticin, stably transduced cells are sub-cloned and three 
reprensentative clones are analysed. Lysates were analyzed with antibodies against hMENA11a, 
hMENAv6, pan-hMENA,VASP or the phosphorylated form of ser157 VASP or ACTIN. 
(C) WB analysis of PANC1- hMENA11a cells transduced with the empty vector (CNTR) or with specific 
siRNA targeting hMENA11a, using antibodies against VASP, the phosphorylated form of ser157 VASP, 
hMENA11a or ACTIN. 
(D) 2D-page analysis of PANC1- hMENA11a cells using antibodies against VASP or the phosphorylated 
form of ser157 VASP. 
(E) 2D-page analysis of PANC1, PANC1- hMENA11a or HPDE cells using antibody against VASP. 
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Figure 11. (A) Representative scheme of 21 aminoacids of 11a exon (in red) pinpointing the two putative 
serines susceptible to phosphorylation. Two different hMENA11a constructs were generated switching the 
two serines to alanine in order to impede phosphorylation. 
(B) WB analysis of PANC1 cells transduced with the empty vector (CNTR) or with specific mutant 
hMENA11a cDNAs (named mut13 and mut14) using antibodies against VASP, the phosphorylated form of 
ser157 VASP or hMENA isoforms. 
 
 
hMENA11a interacts with VASP when Ser 157 is phosphorylated by PKA in normal 
pancreatic cells 
In order to analyze whether hMENA11a directly interact with VASP, we have 
immunoprecipitated protein extracts from HPDE cells with hMENA11a and pan-
hMENA Abs. WB analysis of hMENA11a immunoprecipitates with VASP and P-Ser157 
VASP Abs demontrates that hMENA11a co-immunoprecipitates either with 
phosphorylated VASP or with unphosphorylated VASP (lower band stained by VASP 
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Ab). Immunoprecipitates with Pan-hMENA Ab, which binds both hMENA11a and 
hMENA isoforms in HPDE cells, also evidences a coimmunoprecipitation of VASP, 
but with a lesser amount of the phosphorylated form, indicating a preferential 
interaction between hMENA11a and phosphorylated VASP (Fig. 12A). 
Mena and VASP proteins play an important role in epithelial dynamics (Vasioukhin, 
2000) and VASP Ser157 phosphorylation level is dinamically regulated by PKA during 
cell adhesion (Howe, 2002; Quinlan, 2004; Scott, 2006). VASP phosphorylation 
patterns impact on subcellular protein localization (Benz, 2009), whereas MENA 
phophorylation by PKA in the Ser236 (corresponding to Ser157 in VASP), does not 
affect the protein localization (Loureiro, 2002). The impact of Ser157 phosphorylation 
on the localization of endogenous VASP is investigated in HPDE cells treated with the 
PKA activator forskolin (Forskolin, 25 μM, 20’), buffer solution (DMSO) or PKA 
inhibitor H89 (H89, 50 μM, 60’). WB analysis confirms that HPDE cells express P-
Ser157 VASP (DMSO), whereas Forskolin increased and H89 inhibited 
phosphorylation of Ser157 and Ser239 (data not shown). VASP forms homo- and 
heterotetramers with MENA and EVL (Bachmann, 1999). To understand whether 
hMENA11a and P-Ser157 VASP co-localize, we analyze by immunofluorescence and 
confocal analysis. In untreated HPDE cells, P-Ser157 VASP localizes at focal 
adhesions, while hMENA11a is distributed in cytoplasm and focal adhesion with few 
area of co-localization with P-Ser157 VASP (Fig 12 B). PKA-stimulation strongly 
increases P-Ser157 signal and consistently modifies the subcellular VASP and 
hMENA11a distribution. In fact, hMENA11a disappears from cytoplasmatic sites and 
localizes to focal adhesions and the plasma membrane, together with P-Ser157 VASP 
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(Fig 12 C). On the contrary, the treatment with the PKA inhibitor H89 abrogates P-
Ser157 VASP signal,  as expected, along with the traslocation of hMENA11a  from focal 
adhesion to cytoplasm (Fig. 12 D). Similar results are obtained by staining the cells with 
a pan-hMENA Ab (data not shown). 
These results confirm an interaction between P-Ser157 VASP and hMENA11a in HPDE 
cells, and suggest that the binding of hMENA11a with VASP favour its phosphorylation 
of Ser157 and their localization at focal adhesion is regulated by PKA. 
 
 
 
  
Figure 12. (A) WB analysis of HPDE cell lysate (lane 1) or proteins immunoprecipitated by pre-immune 
rabbit IgG (lane 2), hMENA11a Ab (lane 3) and pan-hMENA Ab (lane 4) with the antibodies reported on 
the left.   
Confocal and phase-contrast analysis of HPDE cells treated with DMSO (B), Forskolin (20’, 25 M) (C) 
or H89 (60’, 50 M) (D), using hMENA11a mAb, (red), P-Ser157 VASP (green) and DAPI (blue). Cells 
were imaged using a Zeiss 710 laser scanning microscope. Magnification 63x.  
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hMENA11a transduction increases Ser157 VASP localization at focal adhesions in 
pancreatic tumor cells 
We hypothesized that hMENA11a presence is necessary for a correct VASP localization 
at focal adhesion. Thus, we compared the P-Ser157 VASP localization in PANC1 and 
PANC1-hMENA11a cells. Confocal analysis shows that hMENA11a ectopic expression in 
PANC1 cells increases P-Ser157 VASP localization at focal adhesion (Fig 13 A), 
although the co-localization of P-Ser157 VASP and hMENA11a is less appreciated 
respect to that observed in HPDE cells. Forskolin treatment increases the co-localization 
between hMENA11a and P-Ser157 VASP at focal adhesion (Fig 13 B), but the treatment 
with  the PKA inhibitor does not induce hMENA11a translocation from focal adhesions 
to the cytoplasm (Fig 13 C), differently from HPDE cells. These results suggest that 
hMENA11a localization at focal adhesion may be indipendent by PKA in PANC1 cells. 
WB analysis of PANC1-hMENA11a cells treated with PKA inhibitor shows a reduction 
of P-Ser157 VASP level, confirming that VASP phosphorylation is mediated by PKA 
in these cells ( data not shown). 
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Figure 13. Confocal and phase-contrast analysis of PANC1 and PANC1-hMENA11a cells treated with 
DMSO (A) or Forskolin (B) or H89 (C), using hMENA11a mAb, (red), ser157 VASP (green) and DAPI 
(blue). Cells were imaged using a Zeiss 710 laser scanning microscope. Magnification 63x.  
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hMENA11a transduction increases cell-matrix adhesion and inhibits cell invasion  
P-Ser157 VASP levels are dynamically regulated during cell-matrix adhesion (Pula, 
2006; Lee and Chung, 2009; Worth, 2010). Thus, we tested the role of hMENA11a may 
have in cell-matrix adhesion.  
After 2h of adhesion on collagen I, PANC1 cells exhibit a low signal of P-Ser157 
VASP, whereas the transduction of hMENA11a induces a higher level of P-Ser157 
VASP (Fig 14 A). Phase-contrast microscopy analysis shows that, after 2h of adhesion 
on collagen I, either PANC1 or PANC1-hMENA11a cells exhibit multiple lamellipodia 
and extensive membrane ruffling, but PANC1-hMENA11a cells extend large lamellae 
with ruffles 30% more than control cells (Fig 14 B). Therefore, we extended analysis of 
cell adhesion at different substrates (collagen type I, collagen type IV, fibronectin) and 
we observed that hMENA11a transduced cells adhere to all the substrates  evaluated 
more rapidly than control cells (Fig 14 C); the number of hMENA11a transduced cells 
double than control after 1,5 h of adhesion. These data evidence that hMENA11a 
expression induces the phosphorylation of VASP at Ser157 with an increased 
lamellipodial extensions and further increased cell-matrix adhesion.  
MENA and VASP proteins are known to play a critical role on cell migration in mouse 
and human (Loureiro, 2002; Wang, 2004) and in mouse model MENA11a mRNA 
dissapeared in disseminated cancer cells (Goswami, 2008). To more directly assess the 
role of  hMENA11a in the regulation of tumorigenic activity, we examined the effects of 
hMENA11a expression on pancreatic cancer cell migration and invasion. Our results 
demonstrate a dramatic reduction of migratory (data not shown) invasive capability in 
hMENA11a clones respect than control cells (Fig  14 D). Interestingly, the clone which 
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express the highest level of hMENA11a is the less invasive. 
 
 
 
Figure 14. (A) PANC1 and PANC1- hMENA11a cells were plated for 2h on tissue culture plates, collagen 
I or Fibronectin prior to lysis and WB analysis with VASP and the phosphorylated form of ser157 Abs.  
(B) Phase-contrast images of PANC1 and PANC1- hMENA11a (clone 13) cells plated for 2h on tissue 
culture plates or collagen I. PANC1- hMENA11a (clone 13) cells exhibit large lamellae with ruffles 30% 
more than control cells (CNTR). 
(C) Graphs depict cell capabilities to adhere on different substrates (Collagen I, IV and Fibronectin). 
 * P<0,001; **P=0,001 
(D) Matrigel invasion assays of PANC1 cells stably transduced with the empty vector (CNTR) or 
hMENA11a (50.000 cells; 24h of invasion). * P=0,002; ** P=0,001 
 
 
ESRP1 transduction resembles hMENA11a effects on VASP phosphorylation, cell-matrix 
adhesion and cell invasion 
ESRP1 and ESRP2, the recently discovered splicing regulatory proteins, abrogate EMT 
  
 
 
 
 76 
program and regulate hMENA splicing in cancer cell lines (Warzecha 2009, 2010; Di 
Modugno, paper submitted). Furthermore, Horiguchi et al demonstrate that TGF1 
mediated EMT induces down-regulation of ESRPs splicing program in PANC1 cells 
(Horiguchi, 2011). Herein, we tested whether ESRP1 transduction into PANC1 cells 
could shift the hMENA splicing program from hMENAv6 to hMENA11a isoform. We 
found that ESRP1 transduction increased hMENA11a and decreased the hMENAv6 
protein levels (Fig 15 A). The additional band recognized either by the anti-hMENA11a 
mAb or the anti-hMENA∆v6 Ab in PANC1 ESRP1 cells, corresponds to the 11a 
inclusion in hMENA∆v6 sequence (Fig 15 A).  
WB analysis of PANC1-ESRP1 evidence that the Ser157 VASP is more phosphorylated 
than control cells, as we observed in hMENA11a transduced cells (Fig 15 A). In parallel 
to an increase of P-Ser157 VASP, ESRP1 transduction induces an increase of adhesive 
properties to different matrix-derived components (Fig 15 B) and a reduction of cell 
invasive capabilities (Fig 15 C), comparable to that observed in PANC1-hMENA11a 
cells. 
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Figure 15. (A) WB analysis of lysates of PANC1 cells transfected with empty vector (CNTR) or with 
ESRP1. After transduction and selection with antibiotic geneticin, stably transduced cells are sub-cloned 
and one reprensentative clone is analysed. Lysates were analyzed with antibodies against hMENA11a, 
hMENAv6, pan-hMENA, VASP or the phosphorylated form of ser157. 
(B) Adhesion assay performed on PANC1 and PANC1-ESRP1 cells plated for 2h on different matrix-
enriched plates. Graphs depict cell capabilities to adhere on different substrates (Collagen I, IV and 
Fibronectin). * P=0,0015; **P=0,0015; *** P=0,0016 
(C) Matrigel invasion assays of PANC1 cells stably transduced with the empty vector (CNTR) or ESRP1 
(50.000 cells; 24h of invasion). * P=0,002. 
(D) WB analysis of HPDE, PANC1 cells stably transduced with the empty vector (CNTR), hMENA11a or 
ESRP1. Cells were grown on collagen for 24 hours before lysis. Lysates were analyzed with antibodies 
against Tyr-396 FAK and total FAK. 
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ESRP1/hMENA11a transduction induces FAK tyr397 dephosphorylation 
There is accumulating evidence that supports an important role of FAK pathway in 
sustaining cell adhesion and invasion of cancer cell (Schaller, 2010). The  
overexpression and phosphorylation of FAK correlates with the increase of cell motility 
and invasion (Crowe, 2004). Based on these results, considerable evidence points to a 
critical role of FAK in cancer. Thus, we compared phosphorylation of Tyr397 FAK in 
parental PANC1 cells plated on collagen I to that of PANC1 cells transduced with 
ESRP1 or hMENA11a. Tyr397 FAK phosphorylation is evident in parental cells and it is 
significant down-regulated ESRP1 or hMENA11a cells, comparable to the “normal” 
HPDE cells (Fig 15 D). 
 
 
hMENA11a is down-regulated in pancreatic primary tumor 
hMENA isoform expression was evaluated by immunohistochemistry using both a pan-
hMENA antibody that recognizes  all the hMENA isoforms, and an antibody specific 
for hMENA11a. The anti-hMENAv6 antibody was unsuitable for 
immunohistochemical evaluation in paraffin-embedded tissues, and we did not succeed 
to either raise suitable antibodies or find other sources. We tested 26 human pancreatic 
tumor tissues demonstrating that hMENA11a expression is expressed only in 4 cases, 
whereas pan-hMENA Ab stain the majority of the cases (table 1). One section from the 
same primitive pancreatic tumor are illustrated in Figure 16, where is evident that 
hMENA11a Ab stains normal ducts (Fig 16 A) whereas cancer cells are negative for 
hMENA11a (Fig 16 B). 
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Considering the pattern of expression identified in cancer cell lines (Fig 7-8), and the 
reactivity of antibodies employed, the group of tumors that are pan-hMENA 
positive/hMENA11a negative would include the tumors that express the hMENA and 
hMENA∆v6 isoforms, with a mesenchymal-like phenotype. In support for this 
hypothesis, immunohistochemical analysis of two cases reported in Figure 17, 
evidences a concomitant expression of hMENA11a and E-CADHERIN in tumor 
negative for VIMENTIN, whereas the hMENA11a and E-CADHERIN negative tumor 
expresses VIMENTIN.    
 
                                 
Table 1. hMENA11a and pan-hMENA protein expression in human pancreatic carcinoma by 
immunohistochemistry. 
  
 
Figure 16.  One section of  a primary pancreatic carcinoma, stained with hMENA11a.(A) normal ducts; 
(B) tumor cells. Magnifications,40x  
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Figure 17.  Two representative cases of  primary pancreatic carcinoma, stained with hMENA11a, E-
CADHERIN or VIMENTIN. Magnifications,40x  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 81 
 
 
 
 
 
 
                                                                                                Chapter 5 - Discussion 
 
 
  
 
 
 
 82 
This PhD work is focused on the study of hMENA splicing program in cancer 
progression focusing on pancreatic cancer as a tumor model in which the disruption of 
tissue homeostasis is an early event along with an early metastatic propensity.  
hMENA along with VASP and EVL comprise the Ena/VASP family of actin regulatory 
proteins, which, acting as tetramers, modulate cell adhesion and migration by 
antagonizing actin capping proteins, bundling actin filaments, and nucleating and 
extending filopodia, underlying important physio-pathological processes, from neural 
development to inflammation, endothelial barrier formation, cancer cell spreading and 
dissemination (Gertler, 1996; Krause, 2003; Applewhite, 2007). Several isoforms have 
been identified for MENA message generating multiple protein isoforms that are 
expressed in specific tissues and cell-types (Gertler, 1996; Tani, 2003; Urbanelli 2006; 
Di Modugno, 2007). By contrast, the EVL gene contains one alternatively spliced exon 
(Lambrechts, 2000) and VASP has none.  
We show here that hMENA alternative splicing is related to EMT process and 
this is in line with recent data demonstrating that hMENA belongs to a cluster of genes 
whose alternative splicing is related to EMT (Warzecha, 2009). Nisticò’s group has 
previously characterized two hMENA isoforms, one 88-kDa isoform defined as 
“classic” and one splice variants, named hMENA11a (90 kDa). Here we report (Di 
Modugno, paper submitted) a novel splice variant of human MENA, named hMENAv6 
(80 kDa) and we suggest that the exon 6 deletion influences protein function and 
regulation by bringing two functional regions closer together, with one site containing a 
PKA Ser phosphorylation residue, and the other site containing the regulatory proline-
rich region. 
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Firstly, we focused our study on an isogenic model of human breast cancer progression  
(Petersen, 1992), and we show that hMENA∆v6 is expressed only in the HMT3522-T4-
2 invasive, but not metastatic tumor cells. Conversely, the premalignant HMT3522-S2 
cells, which are self-sufficient for EGFR signalling, express the epithelial-associated 
hMENA11a isoform. We find that ‘phenotypic reversion’ of malignant HMT3522-T4-2 
cells using different pharmacological inhibitors of the EGFR, which restores apicobasal 
polarity and induces growth arrest, leads to concurrent down-regulation of all the 
hMENA isoforms. On the other hand, hMENA isoforms are not expressed by non-
malignant HMT3522-S1 cells, in agreement with previous results that hMENA is not 
expressed in normal breast tissues or in low risk benign breast lesions as detected by a 
pan-hMENA antibody, recognizing all the hMENA isoforms (Di Modugno 2004).  
Furthermore, a wide analysis on 2D cancer cell lines shows that hMENA11a 
expression is usually associated with breast and cervix cancer cell lines that express E-
CADHERIN, whereas hMENAv6 is expressed in those cancer cells displaying EMT 
features and migratory behaviour. These data suggest that hMENA11a and hMENAv6 
can identify cancer cells with non-invasive and invasive phenotypes, respectively. 
We then focused the study on pancreatic cancer, one of the most lethal cancer. 
Pancreatic ductal adenocarcinoma has dismal prognosis and is highly chemoresistant 
and only 5% of the patients can be surgically resected and long-term survival is directly 
correlated with tumor size. Early detection is the only means to substantially impact 
long-term survival. The human pancreatic malignancy is characterized by invasiveness 
and early metastasis (Hidalgo, 2010). A hallmark in pancreatic ductal adenocarcinoma 
is the development of desmoplasia, a three-dimensional structure supporting epithelial 
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carcinoma cells through an altered ECM, maintained by diffusible paracrine growth 
factors and cytokines, tumor-associated vasculature, inflammatory cells, and stromal 
fibroblasts. The interaction of tumor cells with their microenvironment has been 
suggested to play a pivotal role in tumor progression and acquisition of metastatic 
phenotype (Liotta, 2001). Autocrine and paracrine signals derived from tumor stroma 
may induce EMT (Shintani, 2006), an early event in pancreatic cancer cells (Rhim, 
2012). The molecular mechanisms underlying EMT have been studied extensively in 
the last decade and many studies have been focused on the contribution of changes in 
gene expression to EMT, whereas much less is known regarding the role of alternative 
splicing of mRNA during EMT. Alternative splicing processes provide an additional 
layer of gene regulation that is critical in shaping the EMT process, particularly in 
cancer progression (Nisticò, 2012). A number of genes involved in functions, such as 
cell adhesion, cell motility, and cytoskeletal remodeling, are spliced and play a major 
role in EMT and tumor progression (Venables, 2009; Shapiro, 2011). 
Our study in pancreatic cancer shows that, similar to the results obtained in breast 
cancer cell lines, hMENA “classic” is detected in all the pancreatic tumor cell lines 
tested and in a human pancreatic ductal epithelial cell line (HPDE). The expression of 
hMENA11a, is evident in the ‘normal’ HPDE cell line and to the three cancer cell lines 
positive for expression of E-CADHERIN and negative for expression of VIMENTIN as 
previously reported by Pino, 2008. Herein we show that hMENAv6 is expressed in 
pancreatic cancer cell line negative for hMENA11a and positive for VIMENTIN 
expression, thus providing evidence that also in pancreatic cancer, hMENA11a and 
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hMENAv6 can identify cancer cells with non-invasive and invasive phenotypes, 
respectively.  
MENA and VASP proteins localize to the leading edges of lamellipodia, the tips 
of filopodia, focal adhesions, cell–cell junctions. Localization of these proteins at actin-
rich sites coupled with their ability to promote actin nucleation, suggests that MENA 
and VASP proteins are regulators of actin dynamics in epithelia (Vasioukhin, 2000; 
Linsday, 2007). On the basis of this knowledge, we hypothesized that MENA and or its 
splicing variants may influences the function of the other member of the family VASP 
in the actin-mediated processes such as cell-matrix adhesion and cell invasion. Many 
evidences demonstrate a key role for phospho-VASP mediated regulation of actin 
dynamics in endothelial cells (Benz, 2008), platelets (Pula, 2006), fibroblasts (Worth, 
2010) and epithelial cells (Linsday, 2007) and Ena/VASP family members are 
substrates of nucleotide-dependent protein Kinases PKA, PKG, PKC and AMPK 
(Howe, 2002; Krause, 2003). 
We observed that the Ser157 of VASP is more phosphorylated either in normal or 
pancreatic cancer cell lines with an epithelial phenotype and expressing hMENA11a, 
whereas the hMENA11a negative/hMENAv6 positive PANC1 cell line did not show 
appreciate level of P-Ser157 VASP. By a gain and loss of function, we demonstrate that 
hMENA11a espression is able to induce VASP phosphorylation at Ser157 and that 
hMENA11a transduction in PANC1 cells resembles the pattern of VASP phosphorylation 
observed in HPDE cells. Studies are in progress to elucidate the mechanism underlying 
the influence of hMENA11a expression on VASP phosphorylation. However, results of 
co-IP experiments suggest that the presence of hMENA11a along with VASP renders 
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this protein more susceptible to PKA mediated phosphorylation. One hypothesis may be 
attributable to conformational changes, induced by the presence of the additional 21aa 
peptide of the 11a exon in the tetramer complex. Furthermore, hMENA11a, unlike 
hMENA ‘classic’, is phosphorylated following activation of the EGFR or its other 
family members, suggesting that exon 11a may represent a site for regulation of 
hMENA11a (Di Modugno, 2007, 2010). Thus, we analyzed the effects of hMENA11a 
mutant in PANC1 cells by the substitution of the two putative sites of phosphorylation 
present in 11a peptide from serine to alanine. Biochemical results evidenced that only 
wild type hMENA11a transduction is able to induce VASP phosphorylation at Ser157, 
whereas the two mutants did not affect VASP phosphorylation, thus suggesting that the 
phosphorylation of hMENA11a is relevant for the functional activity of VASP in 
epithelial cells. 
Ser157 is responsible of subcellular VASP localization in spreading endothelial cells 
(Benz, 2009), where is enriched at lamellipodia and focal adhesions in spreading cells 
and the activation of PKA has been shown to increase Ser157 phosphorylation and to 
regulate VASP accumulation at the cell periphery in endothelial cells (Benz, 2008). In 
other cell types it has been observed that Ser157-phosphorylated protein is enriched at 
focal adhesions where it could interact with vinculin, zyxin, and migfilin at these sites 
(Drees, 2000; Hoffman, 2006). On the contrary, the localization of MENA appeared to 
be independent of their pseudophosphorylation status (Loureiro, 2002). The strictly 
connection between hMENA11a and P-Ser157 VASP has been investigated in normal 
and pancreatic cancer cells. Our results demonstrate that P-Ser157 VASP interacts with 
hMENA11a and both proteins localize within focal adhesions in HPDE cells and the 
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PKA activation increases the pool of P-Ser157 VASP and hMENA11a at the cell 
periphery, whereas both proteins disappear from the cell periphery when PKA is 
inhibited. A different picture emerged from our study in PANC1 cancer cell line, where 
P-Ser157 VASP and hMENA11a signals are almost undetectable in unstimulated cells. 
When treated with forskolin, PANC1 cells show an increase of VASP phosphorylation, 
whereas only few cells, respect to HPDE ‘normal’ cells show P-Ser157 VASP localized 
at the cell periphery. hMENA11a transduction rescues the level of P-Ser 157, although 
only in PKA stimulated cells there is an appreciate co-localization between P-Ser157 
VASP and hMENA11a, whereas the treatment with  the PKA inhibitor does not induce 
hMENA11a translocation from focal adhesions to the cytoplasm, differently from HPDE 
cells, suggesting that hMENA11a localization at focal adhesion may be indipendent by 
PKA in transformed cells. 
hMENA message is spliced by ESRP1/2 that regulate splicing of a subset of genes 
involved in actin cytoskeleton organization, cell adhesion and cell motility  contributing 
to the epithelial phenotype in breast and prostatic cancer cells (Warzecha, 2009, 2010) 
Recent results showed that TGF1 mediated EMT induced down-regulation of ESRPs 
splicing program in pancreatic cancer cells (Horiguchi, 2011), suggest us to investigate 
hMENA splicing program in the PANC1 cell line. PANC1 cells transduced with ESRP1 
express hMENA11a and this regulation of hMENA splicing program determines an 
increase of P-Ser157 VASP level.  
At functional level, we analyze whether the hMENA splicing program differently affect 
the ability of PANC1 cells to adhere and invade ECM. hMENA11a or ESRP1 
transduction increases P-Ser157 level in cells plated on collagen type I or fibronectin, 
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together with an increase of cell-matrix adhesion. Phase-contrast images analysis of 
hMENA11a or ESRP1 transductant cells shows that during collagen I-reattachment, cells 
exhibit multiple lamellipodia and extensive membrane ruffling and hMENA11a or 
ESRP1 transduced cells spread and extended large lamellae more than control cells. 
Furthermore, Ena/VASP proteins are known to play a critical role on cell migration in 
mouse and human (Loureiro, 2002; Wang, 2004) and in mouse model Mena11a mRNA 
dissapeared in disseminated cancer cells (Goswami, 2008). To more directly assess the 
role of  hMENA11a in the regulation of tumorigenic activity, we examined the effects of 
hMENA11a expression on pancreatic cancer cell migration and invasion. hMENA11a or 
ESRP1 transduction determines a reduction of cancer cell invasion in a BM-coated 
Boyden chamber. 
Intracellular VASP redistribution and removal from cell periphery in pancreatic cancer 
cells, destabilizes actin-mediated processes such as cell-matrix adhesion and cell 
invasion, which are tightly regulated by integrin signaling and downstream effectors, 
such as FAK (Schaller, 2010). Adhesion of cells on a variety of ECM proteins, leads to 
an increase in tyrosine phosphorylation and activation of FAK (Schaller, 2010). 
Furthermore, suppression of adhesion induced tyrosine phosphorylation of FAK may 
interrupt cancer cell-ECM interactions and affect the invasive and metastatic potential 
of cancer cells. In addition, overexpression and phosphorylation of FAK correlates with 
the increase of cell motility and invasion (Crowe, 2004). We examined the activation of 
FAK in ESRP1 or hMENA11a transduced cells, plated on Collagen I and from WB 
analysis evinces that the level of FAK phosphorylation goes down in ESRP1 or 
hMENA11a cells, as well as in HPDE cells, respect than parental PANC1 cells.  
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In summary, we have shown how hMENA11a regulates VASP phosphorylation at 
Ser157, the favourite PKA site and the phosphorylation at this site favors VASP and 
hMENA11a localization to focal adhesions and lamellipodia as cells spread. Therefore, 
this study evidences an additional layer of regulation of these processes, since hMENA 
splicing perturbation in cancer cells may promote effects either in VASP 
phosphorylation or in FAK signaling. As splicing studies evolve, this study paves the 
way for defining hMENA splicing and its regulation as promising new biomarkers of 
invasiveness. Combined with other clinico-pathological markers, hMENA and its 
spliced forms may improve the early diagnosis of pancreatic and breast cancer and 
efficacious clinical decision for patient  treatment. 
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